| 1 | treat | 13,745 |
| 2 | diagnose | 1,202 |
| 3 | infinity | 207 |
| 4 | intubate | 85 |
| 5 | treat/harm | 46 |
| 6 | rehabilitate | 42 |
| 7 | cleanse | 18 |
| 8 | self-medicate | 15 |
| 9 | self-treat | 15 |
| 10 | subdivide | 14 |
| 11 | downstage | 13 |
| 12 | hospitalize | 11 |
| 13 | perfuse | 11 |
| 14 | retrain | 11 |
| 15 | feign | 9 |
| 16 | prevent/treat | 9 |
| 17 | bathe | 8 |
| 18 | relocate | 8 |
| 19 | colophony | 7 |
| 20 | off-reserve | 5 |
| 21 | overtreat | 5 |
| 22 | 12-y-old | 4 |
| 23 | distalise | 4 |
| 24 | est-ml | 4 |
| 25 | ltra+ics | 4 |
| 26 | pseudo-placebo | 4 |
| 27 | 20-year-olds | 3 |
| 28 | 29-year-olds | 3 |
| 29 | 5·0×10 | 3 |
| 30 | ac-c | 3 |
| 31 | first-and-subsequent | 3 |
| 32 | gain/gain | 3 |
| 33 | gedvdisplayed | 3 |
| 34 | hc-c | 3 |
| 35 | inscribe | 3 |
| 36 | lopinavir/ritonavir/zidovudine/lamivudine | 3 |
| 37 | o3o6 | 3 |
| 38 | objectivize | 3 |
| 39 | osseointegrate | 3 |
| 40 | oxidise | 3 |
| 41 | zymodeme | 3 |
| 42 | 0.1/10 | 2 |
| 43 | 1,3,5-triarylbenzenes | 2 |
| 44 | 12/2010 | 2 |
| 45 | 15-month-olds | 2 |
| 46 | 18/100,000 | 2 |
| 47 | 2.8+/-0.1 | 2 |
| 48 | 207pg/ml | 2 |
| 49 | 2119bp | 2 |
| 50 | 32-month-old | 2 |
| 51 | 36fr | 2 |
| 52 | 4.2±2.3 | 2 |
| 53 | 59-month-old | 2 |
| 54 | 7,880 | 2 |
| 55 | 7098 | 2 |
| 56 | 97-fold | 2 |
| 57 | aβ-negative | 2 |
| 58 | bacillosporin | 2 |
| 59 | chemosensitize | 2 |
| 60 | disordered-eating | 2 |
| 61 | epoxydation | 2 |
| 62 | es/lc | 2 |
| 63 | functionalise | 2 |
| 64 | gd21 | 2 |
| 65 | help/harm | 2 |
| 66 | hf/6-31g++ | 2 |
| 67 | ima/height | 2 |
| 68 | impingement-related | 2 |
| 69 | intuiting | 2 |
| 70 | later-borns | 2 |
| 71 | nonrelational | 2 |
| 72 | offload | 2 |
| 73 | ofloxacin/metronidazole | 2 |
| 74 | permitsubgroup | 2 |
| 75 | placebo/warfarin | 2 |
| 76 | prevent/control | 2 |
| 77 | resequence | 2 |
| 78 | self-heat | 2 |
| 79 | self-inject | 2 |
| 80 | smectic-a | 2 |
| 81 | symbolise | 2 |
| 82 | t-end | 2 |
| 83 | thermometrically | 2 |
| 84 | tolerability/response | 2 |
| 85 | treat/manage | 2 |
| 86 | usa1100 | 2 |
| 87 | ''early | 1 |
| 88 | +6.01 | 1 |
| 89 | -0.14×10 | 1 |
| 90 | -0.28±0.68 | 1 |
| 91 | -1.21°/s | 1 |
| 92 | -1.58°/s | 1 |
| 93 | -12.97 | 1 |
| 94 | -2.96°/s | 1 |
| 95 | -23.8+/-3.8 | 1 |
| 96 | -24.7+/-2.4 | 1 |
| 97 | -3.10log | 1 |
| 98 | -3.29°/s | 1 |
| 99 | -32.60 | 1 |
| 100 | -39.55 | 1 |
| 101 | -50mmhg | 1 |
| 102 | .84l | 1 |
| 103 | .99l | 1 |
| 104 | 0.003±0.01 | 1 |
| 105 | 0.08mgl | 1 |
| 106 | 0.125s | 1 |
| 107 | 0.25±0.10 | 1 |
| 108 | 0.27+/-0.05 | 1 |
| 109 | 0.40+/-0.07 | 1 |
| 110 | 0.43h | 1 |
| 111 | 0.47+/-0.44 | 1 |
| 112 | 0.4d | 1 |
| 113 | 0.56+/-0.82 | 1 |
| 114 | 0.56μgg | 1 |
| 115 | 0.58μgg | 1 |
| 116 | 0.63±0.16 | 1 |
| 117 | 0.64±0.02 | 1 |
| 118 | 0.67/1000 | 1 |
| 119 | 0.6941 | 1 |
| 120 | 0.6ngg | 1 |
| 121 | 0.72+/-0.33 | 1 |
| 122 | 0.72±1.23 | 1 |
| 123 | 0.73lkg | 1 |
| 124 | 0.7425 | 1 |
| 125 | 0.76mm | 1 |
| 126 | 0.76μgg | 1 |
| 127 | 0.78±0.96 | 1 |
| 128 | 0.81±0.14 | 1 |
| 129 | 0.8372 | 1 |
| 130 | 0.86±0.10 | 1 |
| 131 | 0.87±024 | 1 |
| 132 | 0.89+/-0.19 | 1 |
| 133 | 0.8iu/ml | 1 |
| 134 | 0.90mg/l | 1 |
| 135 | 0.92+/-0.80 | 1 |
| 136 | 0.9365 | 1 |
| 137 | 0.9686 | 1 |
| 138 | 0.99d | 1 |
| 139 | 0.9kjm | 1 |
| 140 | 0.9±1g/24h | 1 |
| 141 | 0·632 | 1 |
| 142 | 0·708 | 1 |
| 143 | 1+/-0.3 | 1 |
| 144 | 1,2-epoxy-3-butene | 1 |
| 145 | 1,3,7-trichlorodibenzo-p-dioxin | 1 |
| 146 | 1,3-butadienyl-1-oxoboranes | 1 |
| 147 | 1,3-dichlorodibenzofuran | 1 |
| 148 | 1,3-dihydrothiazolo | 1 |
| 149 | 1-arylsulfonyl | 1 |
| 150 | 1-sqrt | 1 |
| 151 | 1.0+/-0.0 | 1 |
| 152 | 1.0+/-0.6 | 1 |
| 153 | 1.12+/-1.00 | 1 |
| 154 | 1.18+/-0.37 | 1 |
| 155 | 1.2+/-0.44 | 1 |
| 156 | 1.2°/year | 1 |
| 157 | 1.31±0.59 | 1 |
| 158 | 1.4+/-0.6 | 1 |
| 159 | 1.43+/-0.44 | 1 |
| 160 | 1.6-kg | 1 |
| 161 | 1.6046 | 1 |
| 162 | 1.72-fold | 1 |
| 163 | 1.7×10 | 1 |
| 164 | 1.8130 | 1 |
| 165 | 1.8±0.7 | 1 |
| 166 | 1.9+/-0.9 | 1 |
| 167 | 1/123 | 1 |
| 168 | 10/119 | 1 |
| 169 | 101/500 | 1 |
| 170 | 101/502 | 1 |
| 171 | 102.2±26.0cmh | 1 |
| 172 | 102·1 | 1 |
| 173 | 102·3 | 1 |
| 174 | 103+/-36ml/m | 1 |
| 175 | 104·1 | 1 |
| 176 | 105×10 | 1 |
| 177 | 106+/-23 | 1 |
| 178 | 107+/-26 | 1 |
| 179 | 1090.42 | 1 |
| 180 | 11.0mgl | 1 |
| 181 | 11.9±1.7 | 1 |
| 182 | 110nmol/l | 1 |
| 183 | 112/615 | 1 |
| 184 | 114.9±13.5cm | 1 |
| 185 | 115+/-22 | 1 |
| 186 | 1153.87 | 1 |
| 187 | 116+/-26 | 1 |
| 188 | 119+/-27 | 1 |
| 189 | 12.57±9.96 | 1 |
| 190 | 121/203 | 1 |
| 191 | 122.07 | 1 |
| 192 | 123/211 | 1 |
| 193 | 126.26 | 1 |
| 194 | 128±14mmhg | 1 |
| 195 | 129.5±9.4 | 1 |
| 196 | 13,086 | 1 |
| 197 | 13-ethyl-gon-4-ene-3,17-dione | 1 |
| 198 | 13-years-old | 1 |
| 199 | 13.4cm | 1 |
| 200 | 13/352 | 1 |
| 201 | 1311·9 | 1 |
| 202 | 132.8/74.7 | 1 |
| 203 | 133mg/m | 1 |
| 204 | 138/day | 1 |
| 205 | 14-month-olds | 1 |
| 206 | 140+/-20 | 1 |
| 207 | 1400.7+/-241 | 1 |
| 208 | 140db | 1 |
| 209 | 142/92 | 1 |
| 210 | 143.39 | 1 |
| 211 | 144-hour | 1 |
| 212 | 148mmhg | 1 |
| 213 | 14cm×10cm | 1 |
| 214 | 14x10 | 1 |
| 215 | 15+/-4 | 1 |
| 216 | 15-j/cm | 1 |
| 217 | 15.2+/-10.0 | 1 |
| 218 | 15.2/10 | 1 |
| 219 | 15.2±6.7 | 1 |
| 220 | 150+/-54 | 1 |
| 221 | 150ngg | 1 |
| 222 | 150μgl | 1 |
| 223 | 151/day | 1 |
| 224 | 1520.9+/-271.8 | 1 |
| 225 | 154.06 | 1 |
| 226 | 158ml | 1 |
| 227 | 15gl | 1 |
| 228 | 15mj/nm | 1 |
| 229 | 16,925 | 1 |
| 230 | 16.1/1000 | 1 |
| 231 | 16.40+/-3.57 | 1 |
| 232 | 16.7+/-15.3 | 1 |
| 233 | 16/147 | 1 |
| 234 | 16/459 | 1 |
| 235 | 160,000/mm | 1 |
| 236 | 163.15 | 1 |
| 237 | 165.16 | 1 |
| 238 | 17.1±2.8j/m | 1 |
| 239 | 179.9/10 | 1 |
| 240 | 18-y-olds | 1 |
| 241 | 18/96 | 1 |
| 242 | 186+/-92 | 1 |
| 243 | 188.57 | 1 |
| 244 | 19.3±7.1 | 1 |
| 245 | 19.4+/-4.4 | 1 |
| 246 | 19.43±4.07 | 1 |
| 247 | 19/57 | 1 |
| 248 | 192/575 | 1 |
| 249 | 197.90 | 1 |
| 250 | 1gy | 1 |
| 251 | 2,3,5-trichlorobiphenyl | 1 |
| 252 | 2,3-dichloro-5,6-dicyanobenzoquinone | 1 |
| 253 | 2,4,6-trinitrochlorobenzene | 1 |
| 254 | 2,4-dinitrochlorobenzne | 1 |
| 255 | 2-acyl-3- | 1 |
| 256 | 2-allylphenol | 1 |
| 257 | 2-chloroadenine | 1 |
| 258 | 2-hydroxy-3-methylcarbazole | 1 |
| 259 | 2.0mg/g | 1 |
| 260 | 2.0ngg | 1 |
| 261 | 2.1μgl | 1 |
| 262 | 2.3months | 1 |
| 263 | 2.41±0.79 | 1 |
| 264 | 2.58±0.24kg | 1 |
| 265 | 2.5l/min/m | 1 |
| 266 | 2.6+/-3.3 | 1 |
| 267 | 2.60+/-0.92l | 1 |
| 268 | 2.6197 | 1 |
| 269 | 2.64+/-0.6 | 1 |
| 270 | 2.67±2.08 | 1 |
| 271 | 2.8+/-1.1 | 1 |
| 272 | 2.884 | 1 |
| 273 | 2.9439 | 1 |
| 274 | 20.40ngml | 1 |
| 275 | 20.6mg·l | 1 |
| 276 | 20/567 | 1 |
| 277 | 200/min | 1 |
| 278 | 20000/km | 1 |
| 279 | 20alpha-hydroxy | 1 |
| 280 | 20α-hydroxy-progesterone | 1 |
| 281 | 21/500 | 1 |
| 282 | 213/1085 | 1 |
| 283 | 218μg/g | 1 |
| 284 | 22,200 | 1 |
| 285 | 22/1000 | 1 |
| 286 | 22/185 | 1 |
| 287 | 220/452 | 1 |
| 288 | 221pm | 1 |
| 289 | 2251.0 | 1 |
| 290 | 228.7ucarr | 1 |
| 291 | 23.0mm | 1 |
| 292 | 23.3±3.6 | 1 |
| 293 | 23.4gl | 1 |
| 294 | 24,500/mm | 1 |
| 295 | 24.1kj/m | 1 |
| 296 | 24.2±7.0 | 1 |
| 297 | 24.4±7.5 | 1 |
| 298 | 24.7°c | 1 |
| 299 | 24.99 | 1 |
| 300 | 2400μgg | 1 |
| 301 | 25-yd | 1 |
| 302 | 250-kda | 1 |
| 303 | 251.87 | 1 |
| 304 | 252.94 | 1 |
| 305 | 258° | 1 |
| 306 | 25gkg | 1 |
| 307 | 26-mo-old | 1 |
| 308 | 26.6±3.0 | 1 |
| 309 | 26.8+/-20.2 | 1 |
| 310 | 260.4×10 | 1 |
| 311 | 262m | 1 |
| 312 | 266.27 | 1 |
| 313 | 27.3°c | 1 |
| 314 | 27.6±3.7 | 1 |
| 315 | 27.96±3.54 | 1 |
| 316 | 276×10 | 1 |
| 317 | 28.6±4.2 | 1 |
| 318 | 295/549 | 1 |
| 319 | 29x10 | 1 |
| 320 | 2h-pyrrolo | 1 |
| 321 | 3,3',5'-triiodothyronine | 1 |
| 322 | 3,4-dihydropyrano | 1 |
| 323 | 3,4-methylenedioxyphenyl-2-propanone | 1 |
| 324 | 3,4-secofriedel-4 | 1 |
| 325 | 3-amino-1,2,4-triazol-5-one | 1 |
| 326 | 3-amino-5-methylmorpholino-2-oxazolidinone | 1 |
| 327 | 3-benzylidene-1h-pyrrolo | 1 |
| 328 | 3.0+/-0.4h | 1 |
| 329 | 3.07+/-0.43ng/ml | 1 |
| 330 | 3.0805 | 1 |
| 331 | 3.21.min-1.m-2 | 1 |
| 332 | 3.2410 | 1 |
| 333 | 3.29nm | 1 |
| 334 | 3.3+/-1.7 | 1 |
| 335 | 3.4389 | 1 |
| 336 | 3.5×10 | 1 |
| 337 | 3.6062 | 1 |
| 338 | 3.87×10 | 1 |
| 339 | 3.9±2.6 | 1 |
| 340 | 30.1±10.8 | 1 |
| 341 | 30.94±9.16 | 1 |
| 342 | 300/cm | 1 |
| 343 | 306/354 | 1 |
| 344 | 31.8°c | 1 |
| 345 | 312.52 | 1 |
| 346 | 314.0±36.3mohm | 1 |
| 347 | 32/312 | 1 |
| 348 | 32microgl | 1 |
| 349 | 33.0cm | 1 |
| 350 | 34.1+/-6.2 | 1 |
| 351 | 34/74 | 1 |
| 352 | 35-y-old | 1 |
| 353 | 350mg/m | 1 |
| 354 | 356/596 | 1 |
| 355 | 356/616 | 1 |
| 356 | 359-fold | 1 |
| 357 | 36.1±4.8mpa | 1 |
| 358 | 36.28±5.11 | 1 |
| 359 | 36/501 | 1 |
| 360 | 37.6gl | 1 |
| 361 | 372.12 | 1 |
| 362 | 374.4 | 1 |
| 363 | 38.67°c | 1 |
| 364 | 381/500 | 1 |
| 365 | 39.2+/-15.4 | 1 |
| 366 | 392±27 | 1 |
| 367 | 397±23ms | 1 |
| 368 | 4,27-diacetyl-wa | 1 |
| 369 | 4-aryl-2- | 1 |
| 370 | 4-hydroxyestrone | 1 |
| 371 | 4-phenyl-1,2,3,6-tetrahydropyridine | 1 |
| 372 | 4.24+/-2.86 | 1 |
| 373 | 4.4-month | 1 |
| 374 | 4.5pmol/l | 1 |
| 375 | 4.7±0.6×10 | 1 |
| 376 | 4.8days | 1 |
| 377 | 40,970 | 1 |
| 378 | 40-0- | 1 |
| 379 | 409±27ms | 1 |
| 380 | 40·1nmoll | 1 |
| 381 | 42,381 | 1 |
| 382 | 432.41 | 1 |
| 383 | 4397.9 | 1 |
| 384 | 442.50 | 1 |
| 385 | 45.1±6.5 | 1 |
| 386 | 46-yr-old | 1 |
| 387 | 46.2kj/m | 1 |
| 388 | 47+/-7ml/m | 1 |
| 389 | 47.0ml/min/1.73m | 1 |
| 390 | 478.4/10 | 1 |
| 391 | 47·8nmoll | 1 |
| 392 | 48+/-7ml/m | 1 |
| 393 | 485.10 | 1 |
| 394 | 48±12mmhg | 1 |
| 395 | 49+/-24ml/m | 1 |
| 396 | 49.2±21.1cmh | 1 |
| 397 | 492,876 | 1 |
| 398 | 4938ngg | 1 |
| 399 | 4·39 | 1 |
| 400 | 5'4 | 1 |
| 401 | 5'9 | 1 |
| 402 | 5,7:7,13-dimethanopyrazolo | 1 |
| 403 | 5-aminomethyl-oxazolidine-2,4-dione | 1 |
| 404 | 5.2/1,000 | 1 |
| 405 | 5.5/day | 1 |
| 406 | 5.53n | 1 |
| 407 | 5.5×10 | 1 |
| 408 | 5.63±1.6 | 1 |
| 409 | 5/790 | 1 |
| 410 | 50months | 1 |
| 411 | 51.9/week | 1 |
| 412 | 52.7/10 | 1 |
| 413 | 524/542 | 1 |
| 414 | 52×10 | 1 |
| 415 | 54.2/10 | 1 |
| 416 | 54.28 | 1 |
| 417 | 540-day | 1 |
| 418 | 58.5±7.3 | 1 |
| 419 | 58.8n | 1 |
| 420 | 594.37±1,087.30 | 1 |
| 421 | 59±14mmol/mol | 1 |
| 422 | 5mgl | 1 |
| 423 | 5·46 | 1 |
| 424 | 5·57 | 1 |
| 425 | 6-azabicyclo | 1 |
| 426 | 6.0+/-1.24 | 1 |
| 427 | 6.07±0.76 | 1 |
| 428 | 6.2×10 | 1 |
| 429 | 6.42n | 1 |
| 430 | 6.54+/-1.27 | 1 |
| 431 | 6.6×10 | 1 |
| 432 | 6.7975 | 1 |
| 433 | 6/470 | 1 |
| 434 | 60,672 | 1 |
| 435 | 607.3 | 1 |
| 436 | 60mbar | 1 |
| 437 | 63,264 | 1 |
| 438 | 63.2microm/l | 1 |
| 439 | 63.8×10 | 1 |
| 440 | 673.518g/cm | 1 |
| 441 | 68.38 | 1 |
| 442 | 686/10 | 1 |
| 443 | 68±11mm | 1 |
| 444 | 6mgl | 1 |
| 445 | 6·64 | 1 |
| 446 | 7.36±0.02 | 1 |
| 447 | 7.3±2.5 | 1 |
| 448 | 7.4+/-1.51 | 1 |
| 449 | 7.5696 | 1 |
| 450 | 7.5±5.3 | 1 |
| 451 | 7.8-millisecond | 1 |
| 452 | 7.96-fold | 1 |
| 453 | 70/135 | 1 |
| 454 | 708.71 | 1 |
| 455 | 7080 | 1 |
| 456 | 72hpc | 1 |
| 457 | 74.94 | 1 |
| 458 | 75.20ngml | 1 |
| 459 | 76.3/100 | 1 |
| 460 | 774.17 | 1 |
| 461 | 787,527 | 1 |
| 462 | 790.0 | 1 |
| 463 | 795.61 | 1 |
| 464 | 79±7mmhg | 1 |
| 465 | 8.0/1000 | 1 |
| 466 | 8.0gdl | 1 |
| 467 | 8.5+/-1.8 | 1 |
| 468 | 8.8×10 | 1 |
| 469 | 80-cm | 1 |
| 470 | 801.4 | 1 |
| 471 | 829.5 | 1 |
| 472 | 8336 | 1 |
| 473 | 8440 | 1 |
| 474 | 84·5nmoll | 1 |
| 475 | 85.734 | 1 |
| 476 | 87+/-15 | 1 |
| 477 | 88/211 | 1 |
| 478 | 882.7 | 1 |
| 479 | 8·10 | 1 |
| 480 | 8·82 | 1 |
| 481 | 9.0cm | 1 |
| 482 | 9.5+/-9.1 | 1 |
| 483 | 9.7/10 | 1 |
| 484 | 9.9×10 | 1 |
| 485 | 9/1 | 1 |
| 486 | 92mm | 1 |
| 487 | 93+/-14 | 1 |
| 488 | 934/1049 | 1 |
| 489 | 947/1048 | 1 |
| 490 | 980-1425×10 | 1 |
| 491 | 9msw | 1 |
| 492 | 9α-hydroxy-1,4-androstadiene-3,17-dione | 1 |
| 493 | a/chicken/vietnam/ncvd-ka423/2013 | 1 |
| 494 | abbreviated-course | 1 |
| 495 | acrania | 1 |
| 496 | air-conducted | 1 |
| 497 | aldrithiol-2 | 1 |
| 498 | ali/acute | 1 |
| 499 | allevate | 1 |
| 500 | allievate | 1 |
| 501 | alprazolam+exposure | 1 |
| 502 | amicacine | 1 |
| 503 | amino-group-activated | 1 |
| 504 | aml/om+hydrochlorothiazide | 1 |
| 505 | amoxicilin/clavanulate | 1 |
| 506 | amoxicillin/ampicillin | 1 |
| 507 | amoxycillin+clavulanate | 1 |
| 508 | androst-1,4-diene-3,17-dione | 1 |
| 509 | antagonist.. | 1 |
| 510 | apetala2.12 | 1 |
| 511 | applicate | 1 |
| 512 | approxjgiate | 1 |
| 513 | ar-saline | 1 |
| 514 | ari-piprazole | 1 |
| 515 | arterial-elastance | 1 |
| 516 | asialoglycoprotein | 1 |
| 517 | atazanavir/emtricitabine/didanosine-ec | 1 |
| 518 | auto-cure | 1 |
| 519 | autonomic/hypoxemia-driven | 1 |
| 520 | autosomal-co-dominant | 1 |
| 521 | barostat-mediated | 1 |
| 522 | bas=5.4 | 1 |
| 523 | bcs+wbi | 1 |
| 524 | better-targeted | 1 |
| 525 | biomedically-defined | 1 |
| 526 | bmt-induced | 1 |
| 527 | bqa | 1 |
| 528 | bt- | 1 |
| 529 | budbreak | 1 |
| 530 | but-1-ene-3-yne | 1 |
| 531 | c57bl6/wild | 1 |
| 532 | carboxymethyl-l-arginine | 1 |
| 533 | cbtp+tau | 1 |
| 534 | cefamezin | 1 |
| 535 | centre-involving | 1 |
| 536 | chemo-somatosensory | 1 |
| 537 | chloroquine-sulfadoxine/pyrimethamine | 1 |
| 538 | cns-targeted | 1 |
| 539 | comparison-target | 1 |
| 540 | confirm/exclude | 1 |
| 541 | cop-cvp | 1 |
| 542 | correct/augment | 1 |
| 543 | cortrosyn | 1 |
| 544 | crm-197 | 1 |
| 545 | cross-infect | 1 |
| 546 | ctg-treated | 1 |
| 547 | d-depletion | 1 |
| 548 | d07-d09 | 1 |
| 549 | d4t/didanosine | 1 |
| 550 | dehydration29a | 1 |
| 551 | dehydropeptidase-1 | 1 |
| 552 | delayed-wbi | 1 |
| 553 | dementi | 1 |
| 554 | denigrate | 1 |
| 555 | des-cladinose-azithromycin | 1 |
| 556 | diagnose/counsel | 1 |
| 557 | dibenzo-α-pyrones | 1 |
| 558 | diethyl-nitrosoamine | 1 |
| 559 | different-day | 1 |
| 560 | dihydroartemisinin-napthoquine-trimethoprim | 1 |
| 561 | direct-measurement | 1 |
| 562 | dphr | 1 |
| 563 | dwi-sequences | 1 |
| 564 | efavirenz/lamivudine/zidovudine | 1 |
| 565 | electrically-inducible | 1 |
| 566 | embalm | 1 |
| 567 | enacapsulate | 1 |
| 568 | endartectomy | 1 |
| 569 | endosystole | 1 |
| 570 | enyonini | 1 |
| 571 | epirubicin/vinorelbine | 1 |
| 572 | euro448.23 | 1 |
| 573 | evalu-ate | 1 |
| 574 | factor/cluster | 1 |
| 575 | faroese | 1 |
| 576 | fever-ranged | 1 |
| 577 | ff8.600 | 1 |
| 578 | formyl-methionyl-leucyl-phenylalanine | 1 |
| 579 | g194 | 1 |
| 580 | gabepentin | 1 |
| 581 | galium-aluminium-arsenide | 1 |
| 582 | galα1,3-galβ1-4glcnac-r | 1 |
| 583 | gamma-aminobutyric-acid | 1 |
| 584 | gauche-gauche | 1 |
| 585 | geha | 1 |
| 586 | gg-homozygotes | 1 |
| 587 | girinimbine | 1 |
| 588 | glcnacα-o-po | 1 |
| 589 | gpfi | 1 |
| 590 | group-assistant-purification | 1 |
| 591 | growth-transforms | 1 |
| 592 | h2o+glycine | 1 |
| 593 | harbone | 1 |
| 594 | harm=166 | 1 |
| 595 | harm=49 | 1 |
| 596 | harm=59 | 1 |
| 597 | have/had | 1 |
| 598 | heat-sterilize | 1 |
| 599 | hemagglutinination-inhibition | 1 |
| 600 | hepatoma-free | 1 |
| 601 | hexabenzyl-hexaazaisowurtzitane | 1 |
| 602 | high-cho/high-gi | 1 |
| 603 | high-intervention | 1 |
| 604 | hmive | 1 |
| 605 | hpsec-malls-ri | 1 |
| 606 | hsp90-depleted | 1 |
| 607 | hyperglycaemia/ | 1 |
| 608 | hypersensitivity-inducing | 1 |
| 609 | imepenem | 1 |
| 610 | immunosilent | 1 |
| 611 | infrasphincteric | 1 |
| 612 | interweaves | 1 |
| 613 | isopropoxyethanol | 1 |
| 614 | jug-like | 1 |
| 615 | k=7.9 | 1 |
| 616 | kainic-acid | 1 |
| 617 | keyality | 1 |
| 618 | kstep3 | 1 |
| 619 | l-alpha-acetylmethadol | 1 |
| 620 | l-methyl-4-phenylpyridinium | 1 |
| 621 | late-pubertal | 1 |
| 622 | lbh589·hcl | 1 |
| 623 | letrozole/everolimus | 1 |
| 624 | levo-dopa | 1 |
| 625 | lig1 | 1 |
| 626 | lithium-provoked | 1 |
| 627 | lmwh-associated | 1 |
| 628 | lysolecithin-induced | 1 |
| 629 | macrolides-lincosamides | 1 |
| 630 | mahdiyeh | 1 |
| 631 | malefactor | 1 |
| 632 | mcd-related | 1 |
| 633 | metformin+lifestyle | 1 |
| 634 | methoxyethanol | 1 |
| 635 | mid-parts | 1 |
| 636 | midannulus | 1 |
| 637 | mis-communication | 1 |
| 638 | mitoguazone | 1 |
| 639 | mocebpa-mutated | 1 |
| 640 | moderate-stage | 1 |
| 641 | monoxidine | 1 |
| 642 | more-active/low-risk | 1 |
| 643 | morphoquantitative | 1 |
| 644 | myobloc® | 1 |
| 645 | n-methyl-n'-nitro-n'-nitrosoguanidine | 1 |
| 646 | n=30/53 | 1 |
| 647 | n=32/53 | 1 |
| 648 | n=37/106 | 1 |
| 649 | n=62/106 | 1 |
| 650 | nepp-spd | 1 |
| 651 | nhs-post | 1 |
| 652 | nickel-cadmium | 1 |
| 653 | nil·4h2o | 1 |
| 654 | nitrosalbutamol | 1 |
| 655 | non-afternoon-snackers | 1 |
| 656 | non-cf-guided | 1 |
| 657 | non-evslns | 1 |
| 658 | non-food-advertising | 1 |
| 659 | non-gauze | 1 |
| 660 | non-harvesters | 1 |
| 661 | non-ignorability | 1 |
| 662 | non-normoalbuminuric | 1 |
| 663 | nonhyperdiploid-mm | 1 |
| 664 | nonrollover | 1 |
| 665 | nonsupplementation | 1 |
| 666 | normtensives | 1 |
| 667 | not-so-good | 1 |
| 668 | ns40 | 1 |
| 669 | ntrti-induced | 1 |
| 670 | octamer-4 | 1 |
| 671 | one-eyed-pinhead | 1 |
| 672 | opcab-nonconverted | 1 |
| 673 | ortho-c6h4 | 1 |
| 674 | over-stratification | 1 |
| 675 | overconstrain | 1 |
| 676 | oxacillins | 1 |
| 677 | paclitaxel/bevacizumab | 1 |
| 678 | pads/tampons | 1 |
| 679 | panting-induced | 1 |
| 680 | para-chloraniline | 1 |
| 681 | paramomicine | 1 |
| 682 | pathogen-elicited | 1 |
| 683 | pd30 | 1 |
| 684 | perfluorooctanoate | 1 |
| 685 | perindopril- | 1 |
| 686 | pf-tafluprost | 1 |
| 687 | photodocument | 1 |
| 688 | phycocyanin-alpha-chain | 1 |
| 689 | phytohaemaglutinin | 1 |
| 690 | placebo/simvastatin | 1 |
| 691 | planning-target-volume | 1 |
| 692 | polyurethan | 1 |
| 693 | post-prophylaxis | 1 |
| 694 | postpharyngeal | 1 |
| 695 | pound3,816 | 1 |
| 696 | pre-hfm | 1 |
| 697 | prevent/reverse | 1 |
| 698 | probucol-untreated | 1 |
| 699 | progeserone | 1 |
| 700 | prolastinæ | 1 |
| 701 | prostascint® | 1 |
| 702 | prp-scrapie | 1 |
| 703 | qianshencong | 1 |
| 704 | quanzhong | 1 |
| 705 | quit-only | 1 |
| 706 | ra=4.52×10 | 1 |
| 707 | radiofrequency/microwave | 1 |
| 708 | radius2 | 1 |
| 709 | rapalogs | 1 |
| 710 | rass-scale | 1 |
| 711 | re-harden | 1 |
| 712 | reactive/affective/defensive/impulsive | 1 |
| 713 | recieve | 1 |
| 714 | redifferentiate | 1 |
| 715 | rehabilitation-group | 1 |
| 716 | remunerate | 1 |
| 717 | reoffend | 1 |
| 718 | rhigf1 | 1 |
| 719 | rib-oriented | 1 |
| 720 | ris2mg+placebo | 1 |
| 721 | rl-3/25 | 1 |
| 722 | rm149 | 1 |
| 723 | rmet+en | 1 |
| 724 | rs4244285 | 1 |
| 725 | ruthenocene | 1 |
| 726 | s146 | 1 |
| 727 | scar-stage | 1 |
| 728 | sch-23390 | 1 |
| 729 | school-type | 1 |
| 730 | sdldl-7 | 1 |
| 731 | self-mutilate | 1 |
| 732 | septic-shock-induced | 1 |
| 733 | severe-grade | 1 |
| 734 | social-pressure | 1 |
| 735 | spd-130 | 1 |
| 736 | spd-nepp | 1 |
| 737 | ss60 | 1 |
| 738 | ss80 | 1 |
| 739 | st129 | 1 |
| 740 | stenting/dep | 1 |
| 741 | subjective-rectosigmoid | 1 |
| 742 | subsensory/sham | 1 |
| 743 | subspinale | 1 |
| 744 | sulfamethoxazole-trimethropim | 1 |
| 745 | supramodally | 1 |
| 746 | suprasensory/sham | 1 |
| 747 | symptom/quality-of-life | 1 |
| 748 | tac-short-term | 1 |
| 749 | taylor-couette-poiseuille | 1 |
| 750 | tcbt+eap | 1 |
| 751 | teaes-6 | 1 |
| 752 | tegapore | 1 |
| 753 | teniposide+cisplatin | 1 |
| 754 | tenofovir-df/emtricitabine/efavirenz | 1 |
| 755 | tenofovir/emtricitabine/raltegravir | 1 |
| 756 | terbutalin | 1 |
| 757 | tetra-isopropylpyrophosphoramide | 1 |
| 758 | tetramethylsilane | 1 |
| 759 | thrive/malnutrition | 1 |
| 760 | topiramate+risperidone | 1 |
| 761 | trans-3-hydroxy-d-proline | 1 |
| 762 | triamcinolone-injected | 1 |
| 763 | trimethorprim/sulfamethoxazole | 1 |
| 764 | twice-in-a-row | 1 |
| 765 | ufhs | 1 |
| 766 | un'anga | 1 |
| 767 | un-encapsulated | 1 |
| 768 | undress | 1 |
| 769 | untarget | 1 |
| 770 | urgently-needed | 1 |
| 771 | usd1,131 | 1 |
| 772 | v232 | 1 |
| 773 | vibration-stretching | 1 |
| 774 | voll | 1 |
| 775 | vtsm | 1 |
| 776 | walk-157 | 1 |
| 777 | win-together | 1 |
| 778 | wonca-feelings | 1 |
| 779 | work.for | 1 |
| 780 | wrodclaw | 1 |
| 781 | xaa-pro-gln | 1 |
| 782 | xylohexaose | 1 |
| 783 | ypt0-t2 | 1 |
| 784 | yvonne | 1 |
| 785 | zhongzangfu | 1 |
| 786 | zn0.6cu0.2ga1.9in0.3s4 | 1 |
| 787 | ~202.89 | 1 |
| 788 | ~457.81 | 1 |
| 789 | ~780.86 | 1 |
| 790 | £165 | 1 |
| 791 | £9,335 | 1 |
| 792 | £9951/qaly | 1 |
| 793 | α-d-galactopyranosyl- | 1 |
| 794 | α-retinol | 1 |
| 795 | α-y | 1 |
| 796 | α3β4-nachrs | 1 |
| 797 | €12.810 | 1 |
| 798 | €1503 | 1 |
| 799 | €1839 | 1 |
| 800 | €36,007 | 1 |
| 801 | €4,583 | 1 |
| 802 | €68,900 | 1 |
| 803 | ≤0.62/m | 1 |
| 804 | 〈λ〉ζ | 1 |
| 805 | ⩽58×10 | 1 |
| 1 | ''early | 1 |
| 2 | +6.01 | 1 |
| 3 | -0.14×10 | 1 |
| 4 | -0.28±0.68 | 1 |
| 5 | -1.21°/s | 1 |
| 6 | -1.58°/s | 1 |
| 7 | -12.97 | 1 |
| 8 | -2.96°/s | 1 |
| 9 | -23.8+/-3.8 | 1 |
| 10 | -24.7+/-2.4 | 1 |
| 11 | -3.10log | 1 |
| 12 | -3.29°/s | 1 |
| 13 | -32.60 | 1 |
| 14 | -39.55 | 1 |
| 15 | -50mmhg | 1 |
| 16 | .84l | 1 |
| 17 | .99l | 1 |
| 18 | 0.003±0.01 | 1 |
| 19 | 0.08mgl | 1 |
| 20 | 0.1/10 | 2 |
| 21 | 0.125s | 1 |
| 22 | 0.25±0.10 | 1 |
| 23 | 0.27+/-0.05 | 1 |
| 24 | 0.40+/-0.07 | 1 |
| 25 | 0.43h | 1 |
| 26 | 0.47+/-0.44 | 1 |
| 27 | 0.4d | 1 |
| 28 | 0.56+/-0.82 | 1 |
| 29 | 0.56μgg | 1 |
| 30 | 0.58μgg | 1 |
| 31 | 0.63±0.16 | 1 |
| 32 | 0.64±0.02 | 1 |
| 33 | 0.67/1000 | 1 |
| 34 | 0.6941 | 1 |
| 35 | 0.6ngg | 1 |
| 36 | 0.72+/-0.33 | 1 |
| 37 | 0.72±1.23 | 1 |
| 38 | 0.73lkg | 1 |
| 39 | 0.7425 | 1 |
| 40 | 0.76mm | 1 |
| 41 | 0.76μgg | 1 |
| 42 | 0.78±0.96 | 1 |
| 43 | 0.81±0.14 | 1 |
| 44 | 0.8372 | 1 |
| 45 | 0.86±0.10 | 1 |
| 46 | 0.87±024 | 1 |
| 47 | 0.89+/-0.19 | 1 |
| 48 | 0.8iu/ml | 1 |
| 49 | 0.90mg/l | 1 |
| 50 | 0.92+/-0.80 | 1 |
| 51 | 0.9365 | 1 |
| 52 | 0.9686 | 1 |
| 53 | 0.99d | 1 |
| 54 | 0.9kjm | 1 |
| 55 | 0.9±1g/24h | 1 |
| 56 | 0·632 | 1 |
| 57 | 0·708 | 1 |
| 58 | 1+/-0.3 | 1 |
| 59 | 1,2-epoxy-3-butene | 1 |
| 60 | 1,3,5-triarylbenzenes | 2 |
| 61 | 1,3,7-trichlorodibenzo-p-dioxin | 1 |
| 62 | 1,3-butadienyl-1-oxoboranes | 1 |
| 63 | 1,3-dichlorodibenzofuran | 1 |
| 64 | 1,3-dihydrothiazolo | 1 |
| 65 | 1-arylsulfonyl | 1 |
| 66 | 1-sqrt | 1 |
| 67 | 1.0+/-0.0 | 1 |
| 68 | 1.0+/-0.6 | 1 |
| 69 | 1.12+/-1.00 | 1 |
| 70 | 1.18+/-0.37 | 1 |
| 71 | 1.2+/-0.44 | 1 |
| 72 | 1.2°/year | 1 |
| 73 | 1.31±0.59 | 1 |
| 74 | 1.4+/-0.6 | 1 |
| 75 | 1.43+/-0.44 | 1 |
| 76 | 1.6-kg | 1 |
| 77 | 1.6046 | 1 |
| 78 | 1.72-fold | 1 |
| 79 | 1.7×10 | 1 |
| 80 | 1.8130 | 1 |
| 81 | 1.8±0.7 | 1 |
| 82 | 1.9+/-0.9 | 1 |
| 83 | 1/123 | 1 |
| 84 | 10/119 | 1 |
| 85 | 101/500 | 1 |
| 86 | 101/502 | 1 |
| 87 | 102.2±26.0cmh | 1 |
| 88 | 102·1 | 1 |
| 89 | 102·3 | 1 |
| 90 | 103+/-36ml/m | 1 |
| 91 | 104·1 | 1 |
| 92 | 105×10 | 1 |
| 93 | 106+/-23 | 1 |
| 94 | 107+/-26 | 1 |
| 95 | 1090.42 | 1 |
| 96 | 11.0mgl | 1 |
| 97 | 11.9±1.7 | 1 |
| 98 | 110nmol/l | 1 |
| 99 | 112/615 | 1 |
| 100 | 114.9±13.5cm | 1 |
| 101 | 115+/-22 | 1 |
| 102 | 1153.87 | 1 |
| 103 | 116+/-26 | 1 |
| 104 | 119+/-27 | 1 |
| 105 | 12-y-old | 4 |
| 106 | 12.57±9.96 | 1 |
| 107 | 12/2010 | 2 |
| 108 | 121/203 | 1 |
| 109 | 122.07 | 1 |
| 110 | 123/211 | 1 |
| 111 | 126.26 | 1 |
| 112 | 128±14mmhg | 1 |
| 113 | 129.5±9.4 | 1 |
| 114 | 13,086 | 1 |
| 115 | 13-ethyl-gon-4-ene-3,17-dione | 1 |
| 116 | 13-years-old | 1 |
| 117 | 13.4cm | 1 |
| 118 | 13/352 | 1 |
| 119 | 1311·9 | 1 |
| 120 | 132.8/74.7 | 1 |
| 121 | 133mg/m | 1 |
| 122 | 138/day | 1 |
| 123 | 14-month-olds | 1 |
| 124 | 140+/-20 | 1 |
| 125 | 1400.7+/-241 | 1 |
| 126 | 140db | 1 |
| 127 | 142/92 | 1 |
| 128 | 143.39 | 1 |
| 129 | 144-hour | 1 |
| 130 | 148mmhg | 1 |
| 131 | 14cm×10cm | 1 |
| 132 | 14x10 | 1 |
| 133 | 15+/-4 | 1 |
| 134 | 15-j/cm | 1 |
| 135 | 15-month-olds | 2 |
| 136 | 15.2+/-10.0 | 1 |
| 137 | 15.2/10 | 1 |
| 138 | 15.2±6.7 | 1 |
| 139 | 150+/-54 | 1 |
| 140 | 150ngg | 1 |
| 141 | 150μgl | 1 |
| 142 | 151/day | 1 |
| 143 | 1520.9+/-271.8 | 1 |
| 144 | 154.06 | 1 |
| 145 | 158ml | 1 |
| 146 | 15gl | 1 |
| 147 | 15mj/nm | 1 |
| 148 | 16,925 | 1 |
| 149 | 16.1/1000 | 1 |
| 150 | 16.40+/-3.57 | 1 |
| 151 | 16.7+/-15.3 | 1 |
| 152 | 16/147 | 1 |
| 153 | 16/459 | 1 |
| 154 | 160,000/mm | 1 |
| 155 | 163.15 | 1 |
| 156 | 165.16 | 1 |
| 157 | 17.1±2.8j/m | 1 |
| 158 | 179.9/10 | 1 |
| 159 | 18-y-olds | 1 |
| 160 | 18/100,000 | 2 |
| 161 | 18/96 | 1 |
| 162 | 186+/-92 | 1 |
| 163 | 188.57 | 1 |
| 164 | 19.3±7.1 | 1 |
| 165 | 19.4+/-4.4 | 1 |
| 166 | 19.43±4.07 | 1 |
| 167 | 19/57 | 1 |
| 168 | 192/575 | 1 |
| 169 | 197.90 | 1 |
| 170 | 1gy | 1 |
| 171 | 2,3,5-trichlorobiphenyl | 1 |
| 172 | 2,3-dichloro-5,6-dicyanobenzoquinone | 1 |
| 173 | 2,4,6-trinitrochlorobenzene | 1 |
| 174 | 2,4-dinitrochlorobenzne | 1 |
| 175 | 2-acyl-3- | 1 |
| 176 | 2-allylphenol | 1 |
| 177 | 2-chloroadenine | 1 |
| 178 | 2-hydroxy-3-methylcarbazole | 1 |
| 179 | 2.0mg/g | 1 |
| 180 | 2.0ngg | 1 |
| 181 | 2.1μgl | 1 |
| 182 | 2.3months | 1 |
| 183 | 2.41±0.79 | 1 |
| 184 | 2.58±0.24kg | 1 |
| 185 | 2.5l/min/m | 1 |
| 186 | 2.6+/-3.3 | 1 |
| 187 | 2.60+/-0.92l | 1 |
| 188 | 2.6197 | 1 |
| 189 | 2.64+/-0.6 | 1 |
| 190 | 2.67±2.08 | 1 |
| 191 | 2.8+/-0.1 | 2 |
| 192 | 2.8+/-1.1 | 1 |
| 193 | 2.884 | 1 |
| 194 | 2.9439 | 1 |
| 195 | 20-year-olds | 3 |
| 196 | 20.40ngml | 1 |
| 197 | 20.6mg·l | 1 |
| 198 | 20/567 | 1 |
| 199 | 200/min | 1 |
| 200 | 20000/km | 1 |
| 201 | 207pg/ml | 2 |
| 202 | 20alpha-hydroxy | 1 |
| 203 | 20α-hydroxy-progesterone | 1 |
| 204 | 21/500 | 1 |
| 205 | 2119bp | 2 |
| 206 | 213/1085 | 1 |
| 207 | 218μg/g | 1 |
| 208 | 22,200 | 1 |
| 209 | 22/1000 | 1 |
| 210 | 22/185 | 1 |
| 211 | 220/452 | 1 |
| 212 | 221pm | 1 |
| 213 | 2251.0 | 1 |
| 214 | 228.7ucarr | 1 |
| 215 | 23.0mm | 1 |
| 216 | 23.3±3.6 | 1 |
| 217 | 23.4gl | 1 |
| 218 | 24,500/mm | 1 |
| 219 | 24.1kj/m | 1 |
| 220 | 24.2±7.0 | 1 |
| 221 | 24.4±7.5 | 1 |
| 222 | 24.7°c | 1 |
| 223 | 24.99 | 1 |
| 224 | 2400μgg | 1 |
| 225 | 25-yd | 1 |
| 226 | 250-kda | 1 |
| 227 | 251.87 | 1 |
| 228 | 252.94 | 1 |
| 229 | 258° | 1 |
| 230 | 25gkg | 1 |
| 231 | 26-mo-old | 1 |
| 232 | 26.6±3.0 | 1 |
| 233 | 26.8+/-20.2 | 1 |
| 234 | 260.4×10 | 1 |
| 235 | 262m | 1 |
| 236 | 266.27 | 1 |
| 237 | 27.3°c | 1 |
| 238 | 27.6±3.7 | 1 |
| 239 | 27.96±3.54 | 1 |
| 240 | 276×10 | 1 |
| 241 | 28.6±4.2 | 1 |
| 242 | 29-year-olds | 3 |
| 243 | 295/549 | 1 |
| 244 | 29x10 | 1 |
| 245 | 2h-pyrrolo | 1 |
| 246 | 3,3',5'-triiodothyronine | 1 |
| 247 | 3,4-dihydropyrano | 1 |
| 248 | 3,4-methylenedioxyphenyl-2-propanone | 1 |
| 249 | 3,4-secofriedel-4 | 1 |
| 250 | 3-amino-1,2,4-triazol-5-one | 1 |
| 251 | 3-amino-5-methylmorpholino-2-oxazolidinone | 1 |
| 252 | 3-benzylidene-1h-pyrrolo | 1 |
| 253 | 3.0+/-0.4h | 1 |
| 254 | 3.07+/-0.43ng/ml | 1 |
| 255 | 3.0805 | 1 |
| 256 | 3.21.min-1.m-2 | 1 |
| 257 | 3.2410 | 1 |
| 258 | 3.29nm | 1 |
| 259 | 3.3+/-1.7 | 1 |
| 260 | 3.4389 | 1 |
| 261 | 3.5×10 | 1 |
| 262 | 3.6062 | 1 |
| 263 | 3.87×10 | 1 |
| 264 | 3.9±2.6 | 1 |
| 265 | 30.1±10.8 | 1 |
| 266 | 30.94±9.16 | 1 |
| 267 | 300/cm | 1 |
| 268 | 306/354 | 1 |
| 269 | 31.8°c | 1 |
| 270 | 312.52 | 1 |
| 271 | 314.0±36.3mohm | 1 |
| 272 | 32-month-old | 2 |
| 273 | 32/312 | 1 |
| 274 | 32microgl | 1 |
| 275 | 33.0cm | 1 |
| 276 | 34.1+/-6.2 | 1 |
| 277 | 34/74 | 1 |
| 278 | 35-y-old | 1 |
| 279 | 350mg/m | 1 |
| 280 | 356/596 | 1 |
| 281 | 356/616 | 1 |
| 282 | 359-fold | 1 |
| 283 | 36.1±4.8mpa | 1 |
| 284 | 36.28±5.11 | 1 |
| 285 | 36/501 | 1 |
| 286 | 36fr | 2 |
| 287 | 37.6gl | 1 |
| 288 | 372.12 | 1 |
| 289 | 374.4 | 1 |
| 290 | 38.67°c | 1 |
| 291 | 381/500 | 1 |
| 292 | 39.2+/-15.4 | 1 |
| 293 | 392±27 | 1 |
| 294 | 397±23ms | 1 |
| 295 | 4,27-diacetyl-wa | 1 |
| 296 | 4-aryl-2- | 1 |
| 297 | 4-hydroxyestrone | 1 |
| 298 | 4-phenyl-1,2,3,6-tetrahydropyridine | 1 |
| 299 | 4.24+/-2.86 | 1 |
| 300 | 4.2±2.3 | 2 |
| 301 | 4.4-month | 1 |
| 302 | 4.5pmol/l | 1 |
| 303 | 4.7±0.6×10 | 1 |
| 304 | 4.8days | 1 |
| 305 | 40,970 | 1 |
| 306 | 40-0- | 1 |
| 307 | 409±27ms | 1 |
| 308 | 40·1nmoll | 1 |
| 309 | 42,381 | 1 |
| 310 | 432.41 | 1 |
| 311 | 4397.9 | 1 |
| 312 | 442.50 | 1 |
| 313 | 45.1±6.5 | 1 |
| 314 | 46-yr-old | 1 |
| 315 | 46.2kj/m | 1 |
| 316 | 47+/-7ml/m | 1 |
| 317 | 47.0ml/min/1.73m | 1 |
| 318 | 478.4/10 | 1 |
| 319 | 47·8nmoll | 1 |
| 320 | 48+/-7ml/m | 1 |
| 321 | 485.10 | 1 |
| 322 | 48±12mmhg | 1 |
| 323 | 49+/-24ml/m | 1 |
| 324 | 49.2±21.1cmh | 1 |
| 325 | 492,876 | 1 |
| 326 | 4938ngg | 1 |
| 327 | 4·39 | 1 |
| 328 | 5'4 | 1 |
| 329 | 5'9 | 1 |
| 330 | 5,7:7,13-dimethanopyrazolo | 1 |
| 331 | 5-aminomethyl-oxazolidine-2,4-dione | 1 |
| 332 | 5.2/1,000 | 1 |
| 333 | 5.5/day | 1 |
| 334 | 5.53n | 1 |
| 335 | 5.5×10 | 1 |
| 336 | 5.63±1.6 | 1 |
| 337 | 5/790 | 1 |
| 338 | 50months | 1 |
| 339 | 51.9/week | 1 |
| 340 | 52.7/10 | 1 |
| 341 | 524/542 | 1 |
| 342 | 52×10 | 1 |
| 343 | 54.2/10 | 1 |
| 344 | 54.28 | 1 |
| 345 | 540-day | 1 |
| 346 | 58.5±7.3 | 1 |
| 347 | 58.8n | 1 |
| 348 | 59-month-old | 2 |
| 349 | 594.37±1,087.30 | 1 |
| 350 | 59±14mmol/mol | 1 |
| 351 | 5mgl | 1 |
| 352 | 5·0×10 | 3 |
| 353 | 5·46 | 1 |
| 354 | 5·57 | 1 |
| 355 | 6-azabicyclo | 1 |
| 356 | 6.0+/-1.24 | 1 |
| 357 | 6.07±0.76 | 1 |
| 358 | 6.2×10 | 1 |
| 359 | 6.42n | 1 |
| 360 | 6.54+/-1.27 | 1 |
| 361 | 6.6×10 | 1 |
| 362 | 6.7975 | 1 |
| 363 | 6/470 | 1 |
| 364 | 60,672 | 1 |
| 365 | 607.3 | 1 |
| 366 | 60mbar | 1 |
| 367 | 63,264 | 1 |
| 368 | 63.2microm/l | 1 |
| 369 | 63.8×10 | 1 |
| 370 | 673.518g/cm | 1 |
| 371 | 68.38 | 1 |
| 372 | 686/10 | 1 |
| 373 | 68±11mm | 1 |
| 374 | 6mgl | 1 |
| 375 | 6·64 | 1 |
| 376 | 7,880 | 2 |
| 377 | 7.36±0.02 | 1 |
| 378 | 7.3±2.5 | 1 |
| 379 | 7.4+/-1.51 | 1 |
| 380 | 7.5696 | 1 |
| 381 | 7.5±5.3 | 1 |
| 382 | 7.8-millisecond | 1 |
| 383 | 7.96-fold | 1 |
| 384 | 70/135 | 1 |
| 385 | 708.71 | 1 |
| 386 | 7080 | 1 |
| 387 | 7098 | 2 |
| 388 | 72hpc | 1 |
| 389 | 74.94 | 1 |
| 390 | 75.20ngml | 1 |
| 391 | 76.3/100 | 1 |
| 392 | 774.17 | 1 |
| 393 | 787,527 | 1 |
| 394 | 790.0 | 1 |
| 395 | 795.61 | 1 |
| 396 | 79±7mmhg | 1 |
| 397 | 8.0/1000 | 1 |
| 398 | 8.0gdl | 1 |
| 399 | 8.5+/-1.8 | 1 |
| 400 | 8.8×10 | 1 |
| 401 | 80-cm | 1 |
| 402 | 801.4 | 1 |
| 403 | 829.5 | 1 |
| 404 | 8336 | 1 |
| 405 | 8440 | 1 |
| 406 | 84·5nmoll | 1 |
| 407 | 85.734 | 1 |
| 408 | 87+/-15 | 1 |
| 409 | 88/211 | 1 |
| 410 | 882.7 | 1 |
| 411 | 8·10 | 1 |
| 412 | 8·82 | 1 |
| 413 | 9.0cm | 1 |
| 414 | 9.5+/-9.1 | 1 |
| 415 | 9.7/10 | 1 |
| 416 | 9.9×10 | 1 |
| 417 | 9/1 | 1 |
| 418 | 92mm | 1 |
| 419 | 93+/-14 | 1 |
| 420 | 934/1049 | 1 |
| 421 | 947/1048 | 1 |
| 422 | 97-fold | 2 |
| 423 | 980-1425×10 | 1 |
| 424 | 9msw | 1 |
| 425 | 9α-hydroxy-1,4-androstadiene-3,17-dione | 1 |
| 426 | a/chicken/vietnam/ncvd-ka423/2013 | 1 |
| 427 | abbreviated-course | 1 |
| 428 | ac-c | 3 |
| 429 | acrania | 1 |
| 430 | air-conducted | 1 |
| 431 | aldrithiol-2 | 1 |
| 432 | ali/acute | 1 |
| 433 | allevate | 1 |
| 434 | allievate | 1 |
| 435 | alprazolam+exposure | 1 |
| 436 | amicacine | 1 |
| 437 | amino-group-activated | 1 |
| 438 | aml/om+hydrochlorothiazide | 1 |
| 439 | amoxicilin/clavanulate | 1 |
| 440 | amoxicillin/ampicillin | 1 |
| 441 | amoxycillin+clavulanate | 1 |
| 442 | androst-1,4-diene-3,17-dione | 1 |
| 443 | antagonist.. | 1 |
| 444 | apetala2.12 | 1 |
| 445 | applicate | 1 |
| 446 | approxjgiate | 1 |
| 447 | ar-saline | 1 |
| 448 | ari-piprazole | 1 |
| 449 | arterial-elastance | 1 |
| 450 | asialoglycoprotein | 1 |
| 451 | atazanavir/emtricitabine/didanosine-ec | 1 |
| 452 | auto-cure | 1 |
| 453 | autonomic/hypoxemia-driven | 1 |
| 454 | autosomal-co-dominant | 1 |
| 455 | aβ-negative | 2 |
| 456 | bacillosporin | 2 |
| 457 | barostat-mediated | 1 |
| 458 | bas=5.4 | 1 |
| 459 | bathe | 8 |
| 460 | bcs+wbi | 1 |
| 461 | better-targeted | 1 |
| 462 | biomedically-defined | 1 |
| 463 | bmt-induced | 1 |
| 464 | bqa | 1 |
| 465 | bt- | 1 |
| 466 | budbreak | 1 |
| 467 | but-1-ene-3-yne | 1 |
| 468 | c57bl6/wild | 1 |
| 469 | carboxymethyl-l-arginine | 1 |
| 470 | cbtp+tau | 1 |
| 471 | cefamezin | 1 |
| 472 | centre-involving | 1 |
| 473 | chemo-somatosensory | 1 |
| 474 | chemosensitize | 2 |
| 475 | chloroquine-sulfadoxine/pyrimethamine | 1 |
| 476 | cleanse | 18 |
| 477 | cns-targeted | 1 |
| 478 | colophony | 7 |
| 479 | comparison-target | 1 |
| 480 | confirm/exclude | 1 |
| 481 | cop-cvp | 1 |
| 482 | correct/augment | 1 |
| 483 | cortrosyn | 1 |
| 484 | crm-197 | 1 |
| 485 | cross-infect | 1 |
| 486 | ctg-treated | 1 |
| 487 | d-depletion | 1 |
| 488 | d07-d09 | 1 |
| 489 | d4t/didanosine | 1 |
| 490 | dehydration29a | 1 |
| 491 | dehydropeptidase-1 | 1 |
| 492 | delayed-wbi | 1 |
| 493 | dementi | 1 |
| 494 | denigrate | 1 |
| 495 | des-cladinose-azithromycin | 1 |
| 496 | diagnose | 1,202 |
| 497 | diagnose/counsel | 1 |
| 498 | dibenzo-α-pyrones | 1 |
| 499 | diethyl-nitrosoamine | 1 |
| 500 | different-day | 1 |
| 501 | dihydroartemisinin-napthoquine-trimethoprim | 1 |
| 502 | direct-measurement | 1 |
| 503 | disordered-eating | 2 |
| 504 | distalise | 4 |
| 505 | downstage | 13 |
| 506 | dphr | 1 |
| 507 | dwi-sequences | 1 |
| 508 | efavirenz/lamivudine/zidovudine | 1 |
| 509 | electrically-inducible | 1 |
| 510 | embalm | 1 |
| 511 | enacapsulate | 1 |
| 512 | endartectomy | 1 |
| 513 | endosystole | 1 |
| 514 | enyonini | 1 |
| 515 | epirubicin/vinorelbine | 1 |
| 516 | epoxydation | 2 |
| 517 | es/lc | 2 |
| 518 | est-ml | 4 |
| 519 | euro448.23 | 1 |
| 520 | evalu-ate | 1 |
| 521 | factor/cluster | 1 |
| 522 | faroese | 1 |
| 523 | feign | 9 |
| 524 | fever-ranged | 1 |
| 525 | ff8.600 | 1 |
| 526 | first-and-subsequent | 3 |
| 527 | formyl-methionyl-leucyl-phenylalanine | 1 |
| 528 | functionalise | 2 |
| 529 | g194 | 1 |
| 530 | gabepentin | 1 |
| 531 | gain/gain | 3 |
| 532 | galium-aluminium-arsenide | 1 |
| 533 | galα1,3-galβ1-4glcnac-r | 1 |
| 534 | gamma-aminobutyric-acid | 1 |
| 535 | gauche-gauche | 1 |
| 536 | gd21 | 2 |
| 537 | gedvdisplayed | 3 |
| 538 | geha | 1 |
| 539 | gg-homozygotes | 1 |
| 540 | girinimbine | 1 |
| 541 | glcnacα-o-po | 1 |
| 542 | gpfi | 1 |
| 543 | group-assistant-purification | 1 |
| 544 | growth-transforms | 1 |
| 545 | h2o+glycine | 1 |
| 546 | harbone | 1 |
| 547 | harm=166 | 1 |
| 548 | harm=49 | 1 |
| 549 | harm=59 | 1 |
| 550 | have/had | 1 |
| 551 | hc-c | 3 |
| 552 | heat-sterilize | 1 |
| 553 | help/harm | 2 |
| 554 | hemagglutinination-inhibition | 1 |
| 555 | hepatoma-free | 1 |
| 556 | hexabenzyl-hexaazaisowurtzitane | 1 |
| 557 | hf/6-31g++ | 2 |
| 558 | high-cho/high-gi | 1 |
| 559 | high-intervention | 1 |
| 560 | hmive | 1 |
| 561 | hospitalize | 11 |
| 562 | hpsec-malls-ri | 1 |
| 563 | hsp90-depleted | 1 |
| 564 | hyperglycaemia/ | 1 |
| 565 | hypersensitivity-inducing | 1 |
| 566 | ima/height | 2 |
| 567 | imepenem | 1 |
| 568 | immunosilent | 1 |
| 569 | impingement-related | 2 |
| 570 | infinity | 207 |
| 571 | infrasphincteric | 1 |
| 572 | inscribe | 3 |
| 573 | interweaves | 1 |
| 574 | intubate | 85 |
| 575 | intuiting | 2 |
| 576 | isopropoxyethanol | 1 |
| 577 | jug-like | 1 |
| 578 | k=7.9 | 1 |
| 579 | kainic-acid | 1 |
| 580 | keyality | 1 |
| 581 | kstep3 | 1 |
| 582 | l-alpha-acetylmethadol | 1 |
| 583 | l-methyl-4-phenylpyridinium | 1 |
| 584 | late-pubertal | 1 |
| 585 | later-borns | 2 |
| 586 | lbh589·hcl | 1 |
| 587 | letrozole/everolimus | 1 |
| 588 | levo-dopa | 1 |
| 589 | lig1 | 1 |
| 590 | lithium-provoked | 1 |
| 591 | lmwh-associated | 1 |
| 592 | lopinavir/ritonavir/zidovudine/lamivudine | 3 |
| 593 | ltra+ics | 4 |
| 594 | lysolecithin-induced | 1 |
| 595 | macrolides-lincosamides | 1 |
| 596 | mahdiyeh | 1 |
| 597 | malefactor | 1 |
| 598 | mcd-related | 1 |
| 599 | metformin+lifestyle | 1 |
| 600 | methoxyethanol | 1 |
| 601 | mid-parts | 1 |
| 602 | midannulus | 1 |
| 603 | mis-communication | 1 |
| 604 | mitoguazone | 1 |
| 605 | mocebpa-mutated | 1 |
| 606 | moderate-stage | 1 |
| 607 | monoxidine | 1 |
| 608 | more-active/low-risk | 1 |
| 609 | morphoquantitative | 1 |
| 610 | myobloc® | 1 |
| 611 | n-methyl-n'-nitro-n'-nitrosoguanidine | 1 |
| 612 | n=30/53 | 1 |
| 613 | n=32/53 | 1 |
| 614 | n=37/106 | 1 |
| 615 | n=62/106 | 1 |
| 616 | nepp-spd | 1 |
| 617 | nhs-post | 1 |
| 618 | nickel-cadmium | 1 |
| 619 | nil·4h2o | 1 |
| 620 | nitrosalbutamol | 1 |
| 621 | non-afternoon-snackers | 1 |
| 622 | non-cf-guided | 1 |
| 623 | non-evslns | 1 |
| 624 | non-food-advertising | 1 |
| 625 | non-gauze | 1 |
| 626 | non-harvesters | 1 |
| 627 | non-ignorability | 1 |
| 628 | non-normoalbuminuric | 1 |
| 629 | nonhyperdiploid-mm | 1 |
| 630 | nonrelational | 2 |
| 631 | nonrollover | 1 |
| 632 | nonsupplementation | 1 |
| 633 | normtensives | 1 |
| 634 | not-so-good | 1 |
| 635 | ns40 | 1 |
| 636 | ntrti-induced | 1 |
| 637 | o3o6 | 3 |
| 638 | objectivize | 3 |
| 639 | octamer-4 | 1 |
| 640 | off-reserve | 5 |
| 641 | offload | 2 |
| 642 | ofloxacin/metronidazole | 2 |
| 643 | one-eyed-pinhead | 1 |
| 644 | opcab-nonconverted | 1 |
| 645 | ortho-c6h4 | 1 |
| 646 | osseointegrate | 3 |
| 647 | over-stratification | 1 |
| 648 | overconstrain | 1 |
| 649 | overtreat | 5 |
| 650 | oxacillins | 1 |
| 651 | oxidise | 3 |
| 652 | paclitaxel/bevacizumab | 1 |
| 653 | pads/tampons | 1 |
| 654 | panting-induced | 1 |
| 655 | para-chloraniline | 1 |
| 656 | paramomicine | 1 |
| 657 | pathogen-elicited | 1 |
| 658 | pd30 | 1 |
| 659 | perfluorooctanoate | 1 |
| 660 | perfuse | 11 |
| 661 | perindopril- | 1 |
| 662 | permitsubgroup | 2 |
| 663 | pf-tafluprost | 1 |
| 664 | photodocument | 1 |
| 665 | phycocyanin-alpha-chain | 1 |
| 666 | phytohaemaglutinin | 1 |
| 667 | placebo/simvastatin | 1 |
| 668 | placebo/warfarin | 2 |
| 669 | planning-target-volume | 1 |
| 670 | polyurethan | 1 |
| 671 | post-prophylaxis | 1 |
| 672 | postpharyngeal | 1 |
| 673 | pound3,816 | 1 |
| 674 | pre-hfm | 1 |
| 675 | prevent/control | 2 |
| 676 | prevent/reverse | 1 |
| 677 | prevent/treat | 9 |
| 678 | probucol-untreated | 1 |
| 679 | progeserone | 1 |
| 680 | prolastinæ | 1 |
| 681 | prostascint® | 1 |
| 682 | prp-scrapie | 1 |
| 683 | pseudo-placebo | 4 |
| 684 | qianshencong | 1 |
| 685 | quanzhong | 1 |
| 686 | quit-only | 1 |
| 687 | ra=4.52×10 | 1 |
| 688 | radiofrequency/microwave | 1 |
| 689 | radius2 | 1 |
| 690 | rapalogs | 1 |
| 691 | rass-scale | 1 |
| 692 | re-harden | 1 |
| 693 | reactive/affective/defensive/impulsive | 1 |
| 694 | recieve | 1 |
| 695 | redifferentiate | 1 |
| 696 | rehabilitate | 42 |
| 697 | rehabilitation-group | 1 |
| 698 | relocate | 8 |
| 699 | remunerate | 1 |
| 700 | reoffend | 1 |
| 701 | resequence | 2 |
| 702 | retrain | 11 |
| 703 | rhigf1 | 1 |
| 704 | rib-oriented | 1 |
| 705 | ris2mg+placebo | 1 |
| 706 | rl-3/25 | 1 |
| 707 | rm149 | 1 |
| 708 | rmet+en | 1 |
| 709 | rs4244285 | 1 |
| 710 | ruthenocene | 1 |
| 711 | s146 | 1 |
| 712 | scar-stage | 1 |
| 713 | sch-23390 | 1 |
| 714 | school-type | 1 |
| 715 | sdldl-7 | 1 |
| 716 | self-heat | 2 |
| 717 | self-inject | 2 |
| 718 | self-medicate | 15 |
| 719 | self-mutilate | 1 |
| 720 | self-treat | 15 |
| 721 | septic-shock-induced | 1 |
| 722 | severe-grade | 1 |
| 723 | smectic-a | 2 |
| 724 | social-pressure | 1 |
| 725 | spd-130 | 1 |
| 726 | spd-nepp | 1 |
| 727 | ss60 | 1 |
| 728 | ss80 | 1 |
| 729 | st129 | 1 |
| 730 | stenting/dep | 1 |
| 731 | subdivide | 14 |
| 732 | subjective-rectosigmoid | 1 |
| 733 | subsensory/sham | 1 |
| 734 | subspinale | 1 |
| 735 | sulfamethoxazole-trimethropim | 1 |
| 736 | supramodally | 1 |
| 737 | suprasensory/sham | 1 |
| 738 | symbolise | 2 |
| 739 | symptom/quality-of-life | 1 |
| 740 | t-end | 2 |
| 741 | tac-short-term | 1 |
| 742 | taylor-couette-poiseuille | 1 |
| 743 | tcbt+eap | 1 |
| 744 | teaes-6 | 1 |
| 745 | tegapore | 1 |
| 746 | teniposide+cisplatin | 1 |
| 747 | tenofovir-df/emtricitabine/efavirenz | 1 |
| 748 | tenofovir/emtricitabine/raltegravir | 1 |
| 749 | terbutalin | 1 |
| 750 | tetra-isopropylpyrophosphoramide | 1 |
| 751 | tetramethylsilane | 1 |
| 752 | thermometrically | 2 |
| 753 | thrive/malnutrition | 1 |
| 754 | tolerability/response | 2 |
| 755 | topiramate+risperidone | 1 |
| 756 | trans-3-hydroxy-d-proline | 1 |
| 757 | treat | 13,745 |
| 758 | treat/harm | 46 |
| 759 | treat/manage | 2 |
| 760 | triamcinolone-injected | 1 |
| 761 | trimethorprim/sulfamethoxazole | 1 |
| 762 | twice-in-a-row | 1 |
| 763 | ufhs | 1 |
| 764 | un'anga | 1 |
| 765 | un-encapsulated | 1 |
| 766 | undress | 1 |
| 767 | untarget | 1 |
| 768 | urgently-needed | 1 |
| 769 | usa1100 | 2 |
| 770 | usd1,131 | 1 |
| 771 | v232 | 1 |
| 772 | vibration-stretching | 1 |
| 773 | voll | 1 |
| 774 | vtsm | 1 |
| 775 | walk-157 | 1 |
| 776 | win-together | 1 |
| 777 | wonca-feelings | 1 |
| 778 | work.for | 1 |
| 779 | wrodclaw | 1 |
| 780 | xaa-pro-gln | 1 |
| 781 | xylohexaose | 1 |
| 782 | ypt0-t2 | 1 |
| 783 | yvonne | 1 |
| 784 | zhongzangfu | 1 |
| 785 | zn0.6cu0.2ga1.9in0.3s4 | 1 |
| 786 | zymodeme | 3 |
| 787 | ~202.89 | 1 |
| 788 | ~457.81 | 1 |
| 789 | ~780.86 | 1 |
| 790 | £165 | 1 |
| 791 | £9,335 | 1 |
| 792 | £9951/qaly | 1 |
| 793 | α-d-galactopyranosyl- | 1 |
| 794 | α-retinol | 1 |
| 795 | α-y | 1 |
| 796 | α3β4-nachrs | 1 |
| 797 | €12.810 | 1 |
| 798 | €1503 | 1 |
| 799 | €1839 | 1 |
| 800 | €36,007 | 1 |
| 801 | €4,583 | 1 |
| 802 | €68,900 | 1 |
| 803 | ≤0.62/m | 1 |
| 804 | 〈λ〉ζ | 1 |
| 805 | ⩽58×10 | 1 |
| 1 | hf/6-31g++ | 2 |
| 2 | 40-0- | 1 |
| 3 | 4-aryl-2- | 1 |
| 4 | 2-acyl-3- | 1 |
| 5 | perindopril- | 1 |
| 6 | α-d-galactopyranosyl- | 1 |
| 7 | bt- | 1 |
| 8 | antagonist.. | 1 |
| 9 | hyperglycaemia/ | 1 |
| 10 | 1.0+/-0.0 | 1 |
| 11 | 15.2+/-10.0 | 1 |
| 12 | 790.0 | 1 |
| 13 | 2251.0 | 1 |
| 14 | 26.6±3.0 | 1 |
| 15 | 24.2±7.0 | 1 |
| 16 | 1.12+/-1.00 | 1 |
| 17 | 18/100,000 | 2 |
| 18 | 5.2/1,000 | 1 |
| 19 | 8.0/1000 | 1 |
| 20 | 16.1/1000 | 1 |
| 21 | 22/1000 | 1 |
| 22 | 0.67/1000 | 1 |
| 23 | 76.3/100 | 1 |
| 24 | usa1100 | 2 |
| 25 | 22,200 | 1 |
| 26 | 101/500 | 1 |
| 27 | 21/500 | 1 |
| 28 | 381/500 | 1 |
| 29 | ff8.600 | 1 |
| 30 | €68,900 | 1 |
| 31 | 0.25±0.10 | 1 |
| 32 | 0.86±0.10 | 1 |
| 33 | 485.10 | 1 |
| 34 | 0.1/10 | 2 |
| 35 | 54.2/10 | 1 |
| 36 | 15.2/10 | 1 |
| 37 | 478.4/10 | 1 |
| 38 | 686/10 | 1 |
| 39 | 52.7/10 | 1 |
| 40 | 9.7/10 | 1 |
| 41 | 179.9/10 | 1 |
| 42 | 12/2010 | 2 |
| 43 | 3.2410 | 1 |
| 44 | €12.810 | 1 |
| 45 | 14x10 | 1 |
| 46 | 29x10 | 1 |
| 47 | 5·0×10 | 3 |
| 48 | 6.2×10 | 1 |
| 49 | 52×10 | 1 |
| 50 | ra=4.52×10 | 1 |
| 51 | 260.4×10 | 1 |
| 52 | -0.14×10 | 1 |
| 53 | 3.5×10 | 1 |
| 54 | 5.5×10 | 1 |
| 55 | 105×10 | 1 |
| 56 | 980-1425×10 | 1 |
| 57 | 4.7±0.6×10 | 1 |
| 58 | 6.6×10 | 1 |
| 59 | 276×10 | 1 |
| 60 | 1.7×10 | 1 |
| 61 | 3.87×10 | 1 |
| 62 | 63.8×10 | 1 |
| 63 | 8.8×10 | 1 |
| 64 | ⩽58×10 | 1 |
| 65 | 9.9×10 | 1 |
| 66 | 8·10 | 1 |
| 67 | 140+/-20 | 1 |
| 68 | 594.37±1,087.30 | 1 |
| 69 | spd-130 | 1 |
| 70 | 1.8130 | 1 |
| 71 | pd30 | 1 |
| 72 | 8440 | 1 |
| 73 | ns40 | 1 |
| 74 | 442.50 | 1 |
| 75 | -32.60 | 1 |
| 76 | ss60 | 1 |
| 77 | 6/470 | 1 |
| 78 | 40,970 | 1 |
| 79 | 0.92+/-0.80 | 1 |
| 80 | 7080 | 1 |
| 81 | 7,880 | 2 |
| 82 | ss80 | 1 |
| 83 | 197.90 | 1 |
| 84 | sch-23390 | 1 |
| 85 | 5/790 | 1 |
| 86 | dehydropeptidase-1 | 1 |
| 87 | 2.8+/-0.1 | 2 |
| 88 | 2.8+/-1.1 | 1 |
| 89 | 19.3±7.1 | 1 |
| 90 | 9.5+/-9.1 | 1 |
| 91 | 9/1 | 1 |
| 92 | 0.003±0.01 | 1 |
| 93 | +6.01 | 1 |
| 94 | 36/501 | 1 |
| 95 | 36.28±5.11 | 1 |
| 96 | 123/211 | 1 |
| 97 | 88/211 | 1 |
| 98 | gd21 | 2 |
| 99 | usd1,131 | 1 |
| 100 | 432.41 | 1 |
| 101 | 1400.7+/-241 | 1 |
| 102 | 0.6941 | 1 |
| 103 | 7.4+/-1.51 | 1 |
| 104 | 795.61 | 1 |
| 105 | 708.71 | 1 |
| 106 | ~457.81 | 1 |
| 107 | 42,381 | 1 |
| 108 | rhigf1 | 1 |
| 109 | lig1 | 1 |
| 110 | 102·1 | 1 |
| 111 | 104·1 | 1 |
| 112 | aldrithiol-2 | 1 |
| 113 | 3.21.min-1.m-2 | 1 |
| 114 | 26.8+/-20.2 | 1 |
| 115 | 28.6±4.2 | 1 |
| 116 | 34.1+/-6.2 | 1 |
| 117 | 0.64±0.02 | 1 |
| 118 | 7.36±0.02 | 1 |
| 119 | 101/502 | 1 |
| 120 | 372.12 | 1 |
| 121 | apetala2.12 | 1 |
| 122 | 32/312 | 1 |
| 123 | 115+/-22 | 1 |
| 124 | v232 | 1 |
| 125 | 0·632 | 1 |
| 126 | 1090.42 | 1 |
| 127 | 524/542 | 1 |
| 128 | 312.52 | 1 |
| 129 | 13/352 | 1 |
| 130 | 220/452 | 1 |
| 131 | 3.6062 | 1 |
| 132 | 0.8372 | 1 |
| 133 | 60,672 | 1 |
| 134 | 0.56+/-0.82 | 1 |
| 135 | 8·82 | 1 |
| 136 | 186+/-92 | 1 |
| 137 | 142/92 | 1 |
| 138 | radius2 | 1 |
| 139 | ypt0-t2 | 1 |
| 140 | 1+/-0.3 | 1 |
| 141 | 4.2±2.3 | 2 |
| 142 | 2.6+/-3.3 | 1 |
| 143 | 16.7+/-15.3 | 1 |
| 144 | 7.5±5.3 | 1 |
| 145 | 607.3 | 1 |
| 146 | 58.5±7.3 | 1 |
| 147 | 121/203 | 1 |
| 148 | €1503 | 1 |
| 149 | a/chicken/vietnam/ncvd-ka423/2013 | 1 |
| 150 | 106+/-23 | 1 |
| 151 | 0.72±1.23 | 1 |
| 152 | euro448.23 | 1 |
| 153 | 1/123 | 1 |
| 154 | 0.72+/-0.33 | 1 |
| 155 | n=30/53 | 1 |
| 156 | n=32/53 | 1 |
| 157 | €4,583 | 1 |
| 158 | kstep3 | 1 |
| 159 | 102·3 | 1 |
| 160 | 5'4 | 1 |
| 161 | 15+/-4 | 1 |
| 162 | 3,4-secofriedel-4 | 1 |
| 163 | octamer-4 | 1 |
| 164 | 801.4 | 1 |
| 165 | -24.7+/-2.4 | 1 |
| 166 | 19.4+/-4.4 | 1 |
| 167 | 374.4 | 1 |
| 168 | 39.2+/-15.4 | 1 |
| 169 | bas=5.4 | 1 |
| 170 | 129.5±9.4 | 1 |
| 171 | 93+/-14 | 1 |
| 172 | 0.81±0.14 | 1 |
| 173 | 6.0+/-1.24 | 1 |
| 174 | 0.87±024 | 1 |
| 175 | 85.734 | 1 |
| 176 | 1.2+/-0.44 | 1 |
| 177 | 1.43+/-0.44 | 1 |
| 178 | 0.47+/-0.44 | 1 |
| 179 | 150+/-54 | 1 |
| 180 | 27.96±3.54 | 1 |
| 181 | 306/354 | 1 |
| 182 | 63,264 | 1 |
| 183 | 6·64 | 1 |
| 184 | 34/74 | 1 |
| 185 | 2.884 | 1 |
| 186 | 252.94 | 1 |
| 187 | 74.94 | 1 |
| 188 | g194 | 1 |
| 189 | ortho-c6h4 | 1 |
| 190 | zn0.6cu0.2ga1.9in0.3s4 | 1 |
| 191 | 7.3±2.5 | 1 |
| 192 | 45.1±6.5 | 1 |
| 193 | 24.4±7.5 | 1 |
| 194 | 829.5 | 1 |
| 195 | 0.27+/-0.05 | 1 |
| 196 | 3.0805 | 1 |
| 197 | 87+/-15 | 1 |
| 198 | 163.15 | 1 |
| 199 | 112/615 | 1 |
| 200 | rl-3/25 | 1 |
| 201 | 0.7425 | 1 |
| 202 | 16,925 | 1 |
| 203 | 70/135 | 1 |
| 204 | £9,335 | 1 |
| 205 | -39.55 | 1 |
| 206 | £165 | 1 |
| 207 | 0.9365 | 1 |
| 208 | 192/575 | 1 |
| 209 | 6.7975 | 1 |
| 210 | 213/1085 | 1 |
| 211 | 22/185 | 1 |
| 212 | rs4244285 | 1 |
| 213 | teaes-6 | 1 |
| 214 | 1.0+/-0.6 | 1 |
| 215 | 1.4+/-0.6 | 1 |
| 216 | 2.64+/-0.6 | 1 |
| 217 | 5.63±1.6 | 1 |
| 218 | 3.9±2.6 | 1 |
| 219 | 23.3±3.6 | 1 |
| 220 | 154.06 | 1 |
| 221 | n=62/106 | 1 |
| 222 | n=37/106 | 1 |
| 223 | 0.63±0.16 | 1 |
| 224 | 165.16 | 1 |
| 225 | 30.94±9.16 | 1 |
| 226 | 356/616 | 1 |
| 227 | pound3,816 | 1 |
| 228 | 116+/-26 | 1 |
| 229 | 107+/-26 | 1 |
| 230 | 126.26 | 1 |
| 231 | 8336 | 1 |
| 232 | 1.6046 | 1 |
| 233 | s146 | 1 |
| 234 | 5·46 | 1 |
| 235 | harm=166 | 1 |
| 236 | 6.07±0.76 | 1 |
| 237 | 492,876 | 1 |
| 238 | ~780.86 | 1 |
| 239 | 4.24+/-2.86 | 1 |
| 240 | 13,086 | 1 |
| 241 | 0.9686 | 1 |
| 242 | 0.78±0.96 | 1 |
| 243 | 12.57±9.96 | 1 |
| 244 | 18/96 | 1 |
| 245 | 356/596 | 1 |
| 246 | 7.5696 | 1 |
| 247 | o3o6 | 3 |
| 248 | sdldl-7 | 1 |
| 249 | 1.8±0.7 | 1 |
| 250 | 3.3+/-1.7 | 1 |
| 251 | 11.9±1.7 | 1 |
| 252 | 882.7 | 1 |
| 253 | 27.6±3.7 | 1 |
| 254 | 132.8/74.7 | 1 |
| 255 | 15.2±6.7 | 1 |
| 256 | 0.40+/-0.07 | 1 |
| 257 | 122.07 | 1 |
| 258 | 19.43±4.07 | 1 |
| 259 | €36,007 | 1 |
| 260 | 774.17 | 1 |
| 261 | 119+/-27 | 1 |
| 262 | 6.54+/-1.27 | 1 |
| 263 | 266.27 | 1 |
| 264 | 787,527 | 1 |
| 265 | 392±27 | 1 |
| 266 | 1.18+/-0.37 | 1 |
| 267 | 16/147 | 1 |
| 268 | 16.40+/-3.57 | 1 |
| 269 | 188.57 | 1 |
| 270 | 19/57 | 1 |
| 271 | walk-157 | 1 |
| 272 | 5·57 | 1 |
| 273 | 20/567 | 1 |
| 274 | 251.87 | 1 |
| 275 | 1153.87 | 1 |
| 276 | -12.97 | 1 |
| 277 | crm-197 | 1 |
| 278 | 2.6197 | 1 |
| 279 | 30.1±10.8 | 1 |
| 280 | 8.5+/-1.8 | 1 |
| 281 | 1520.9+/-271.8 | 1 |
| 282 | -23.8+/-3.8 | 1 |
| 283 | 2.67±2.08 | 1 |
| 284 | 0·708 | 1 |
| 285 | 54.28 | 1 |
| 286 | 68.38 | 1 |
| 287 | 947/1048 | 1 |
| 288 | -0.28±0.68 | 1 |
| 289 | 7098 | 2 |
| 290 | 5'9 | 1 |
| 291 | 1.9+/-0.9 | 1 |
| 292 | 4397.9 | 1 |
| 293 | k=7.9 | 1 |
| 294 | d07-d09 | 1 |
| 295 | 0.89+/-0.19 | 1 |
| 296 | 10/119 | 1 |
| 297 | st129 | 1 |
| 298 | 143.39 | 1 |
| 299 | 2.9439 | 1 |
| 300 | €1839 | 1 |
| 301 | 4·39 | 1 |
| 302 | 934/1049 | 1 |
| 303 | rm149 | 1 |
| 304 | 295/549 | 1 |
| 305 | harm=49 | 1 |
| 306 | 1.31±0.59 | 1 |
| 307 | 16/459 | 1 |
| 308 | harm=59 | 1 |
| 309 | 2.41±0.79 | 1 |
| 310 | ~202.89 | 1 |
| 311 | 3.4389 | 1 |
| 312 | 24.99 | 1 |
| 313 | 1311·9 | 1 |
| 314 | smectic-a | 2 |
| 315 | dehydration29a | 1 |
| 316 | 250-kda | 1 |
| 317 | un'anga | 1 |
| 318 | geha | 1 |
| 319 | acrania | 1 |
| 320 | 36.1±4.8mpa | 1 |
| 321 | levo-dopa | 1 |
| 322 | bqa | 1 |
| 323 | 4,27-diacetyl-wa | 1 |
| 324 | paclitaxel/bevacizumab | 1 |
| 325 | 140db | 1 |
| 326 | ac-c | 3 |
| 327 | hc-c | 3 |
| 328 | atazanavir/emtricitabine/didanosine-ec | 1 |
| 329 | infrasphincteric | 1 |
| 330 | non-normoalbuminuric | 1 |
| 331 | es/lc | 2 |
| 332 | 72hpc | 1 |
| 333 | 27.3°c | 1 |
| 334 | 24.7°c | 1 |
| 335 | 38.67°c | 1 |
| 336 | 31.8°c | 1 |
| 337 | 0.4d | 1 |
| 338 | 0.99d | 1 |
| 339 | one-eyed-pinhead | 1 |
| 340 | have/had | 1 |
| 341 | offload | 2 |
| 342 | panting-induced | 1 |
| 343 | ntrti-induced | 1 |
| 344 | septic-shock-induced | 1 |
| 345 | lysolecithin-induced | 1 |
| 346 | bmt-induced | 1 |
| 347 | urgently-needed | 1 |
| 348 | non-cf-guided | 1 |
| 349 | fever-ranged | 1 |
| 350 | lithium-provoked | 1 |
| 351 | biomedically-defined | 1 |
| 352 | ctg-treated | 1 |
| 353 | probucol-untreated | 1 |
| 354 | lmwh-associated | 1 |
| 355 | barostat-mediated | 1 |
| 356 | mcd-related | 1 |
| 357 | impingement-related | 2 |
| 358 | un-encapsulated | 1 |
| 359 | mocebpa-mutated | 1 |
| 360 | amino-group-activated | 1 |
| 361 | triamcinolone-injected | 1 |
| 362 | air-conducted | 1 |
| 363 | better-targeted | 1 |
| 364 | cns-targeted | 1 |
| 365 | hsp90-depleted | 1 |
| 366 | pathogen-elicited | 1 |
| 367 | rib-oriented | 1 |
| 368 | opcab-nonconverted | 1 |
| 369 | gedvdisplayed | 3 |
| 370 | kainic-acid | 1 |
| 371 | gamma-aminobutyric-acid | 1 |
| 372 | subjective-rectosigmoid | 1 |
| 373 | c57bl6/wild | 1 |
| 374 | 32-month-old | 2 |
| 375 | 59-month-old | 2 |
| 376 | 26-mo-old | 1 |
| 377 | 46-yr-old | 1 |
| 378 | 13-years-old | 1 |
| 379 | 12-y-old | 4 |
| 380 | 35-y-old | 1 |
| 381 | 1.72-fold | 1 |
| 382 | 7.96-fold | 1 |
| 383 | 97-fold | 2 |
| 384 | 359-fold | 1 |
| 385 | t-end | 2 |
| 386 | reoffend | 1 |
| 387 | 7.8-millisecond | 1 |
| 388 | not-so-good | 1 |
| 389 | nepp-spd | 1 |
| 390 | 25-yd | 1 |
| 391 | inscribe | 3 |
| 392 | arterial-elastance | 1 |
| 393 | resequence | 2 |
| 394 | severe-grade | 1 |
| 395 | tetra-isopropylpyrophosphoramide | 1 |
| 396 | galium-aluminium-arsenide | 1 |
| 397 | subdivide | 14 |
| 398 | aml/om+hydrochlorothiazide | 1 |
| 399 | confirm/exclude | 1 |
| 400 | hepatoma-free | 1 |
| 401 | symptom/quality-of-life | 1 |
| 402 | treat/manage | 2 |
| 403 | moderate-stage | 1 |
| 404 | scar-stage | 1 |
| 405 | downstage | 13 |
| 406 | gauche-gauche | 1 |
| 407 | bathe | 8 |
| 408 | prp-scrapie | 1 |
| 409 | jug-like | 1 |
| 410 | rass-scale | 1 |
| 411 | subspinale | 1 |
| 412 | electrically-inducible | 1 |
| 413 | taylor-couette-poiseuille | 1 |
| 414 | endosystole | 1 |
| 415 | 2-hydroxy-3-methylcarbazole | 1 |
| 416 | ofloxacin/metronidazole | 2 |
| 417 | ari-piprazole | 1 |
| 418 | trimethorprim/sulfamethoxazole | 1 |
| 419 | metformin+lifestyle | 1 |
| 420 | zymodeme | 3 |
| 421 | planning-target-volume | 1 |
| 422 | tetramethylsilane | 1 |
| 423 | hexabenzyl-hexaazaisowurtzitane | 1 |
| 424 | ruthenocene | 1 |
| 425 | 1,2-epoxy-3-butene | 1 |
| 426 | 2,4,6-trinitrochlorobenzene | 1 |
| 427 | epirubicin/vinorelbine | 1 |
| 428 | girinimbine | 1 |
| 429 | amicacine | 1 |
| 430 | paramomicine | 1 |
| 431 | h2o+glycine | 1 |
| 432 | n-methyl-n'-nitro-n'-nitrosoguanidine | 1 |
| 433 | 4-phenyl-1,2,3,6-tetrahydropyridine | 1 |
| 434 | monoxidine | 1 |
| 435 | lopinavir/ritonavir/zidovudine/lamivudine | 3 |
| 436 | efavirenz/lamivudine/zidovudine | 1 |
| 437 | ar-saline | 1 |
| 438 | para-chloraniline | 1 |
| 439 | trans-3-hydroxy-d-proline | 1 |
| 440 | chloroquine-sulfadoxine/pyrimethamine | 1 |
| 441 | diethyl-nitrosoamine | 1 |
| 442 | formyl-methionyl-leucyl-phenylalanine | 1 |
| 443 | 2-chloroadenine | 1 |
| 444 | carboxymethyl-l-arginine | 1 |
| 445 | 3,3',5'-triiodothyronine | 1 |
| 446 | d4t/didanosine | 1 |
| 447 | yvonne | 1 |
| 448 | 3-amino-1,2,4-triazol-5-one | 1 |
| 449 | harbone | 1 |
| 450 | topiramate+risperidone | 1 |
| 451 | 5-aminomethyl-oxazolidine-2,4-dione | 1 |
| 452 | 13-ethyl-gon-4-ene-3,17-dione | 1 |
| 453 | androst-1,4-diene-3,17-dione | 1 |
| 454 | 9α-hydroxy-1,4-androstadiene-3,17-dione | 1 |
| 455 | 3,4-methylenedioxyphenyl-2-propanone | 1 |
| 456 | 3-amino-5-methylmorpholino-2-oxazolidinone | 1 |
| 457 | 2,3-dichloro-5,6-dicyanobenzoquinone | 1 |
| 458 | progeserone | 1 |
| 459 | 20α-hydroxy-progesterone | 1 |
| 460 | 4-hydroxyestrone | 1 |
| 461 | mitoguazone | 1 |
| 462 | but-1-ene-3-yne | 1 |
| 463 | 2,4-dinitrochlorobenzne | 1 |
| 464 | school-type | 1 |
| 465 | tegapore | 1 |
| 466 | auto-cure | 1 |
| 467 | alprazolam+exposure | 1 |
| 468 | social-pressure | 1 |
| 469 | faroese | 1 |
| 470 | oxidise | 3 |
| 471 | functionalise | 2 |
| 472 | distalise | 4 |
| 473 | symbolise | 2 |
| 474 | cleanse | 18 |
| 475 | tolerability/response | 2 |
| 476 | xylohexaose | 1 |
| 477 | diagnose | 1,202 |
| 478 | prevent/reverse | 1 |
| 479 | abbreviated-course | 1 |
| 480 | perfuse | 11 |
| 481 | evalu-ate | 1 |
| 482 | intubate | 85 |
| 483 | self-medicate | 15 |
| 484 | applicate | 1 |
| 485 | relocate | 8 |
| 486 | approxjgiate | 1 |
| 487 | redifferentiate | 1 |
| 488 | self-mutilate | 1 |
| 489 | amoxicilin/clavanulate | 1 |
| 490 | enacapsulate | 1 |
| 491 | amoxycillin+clavulanate | 1 |
| 492 | perfluorooctanoate | 1 |
| 493 | remunerate | 1 |
| 494 | osseointegrate | 3 |
| 495 | denigrate | 1 |
| 496 | rehabilitate | 42 |
| 497 | allievate | 1 |
| 498 | allevate | 1 |
| 499 | ali/acute | 1 |
| 500 | radiofrequency/microwave | 1 |
| 501 | recieve | 1 |
| 502 | hmive | 1 |
| 503 | reactive/affective/defensive/impulsive | 1 |
| 504 | aβ-negative | 2 |
| 505 | morphoquantitative | 1 |
| 506 | off-reserve | 5 |
| 507 | hospitalize | 11 |
| 508 | heat-sterilize | 1 |
| 509 | chemosensitize | 2 |
| 510 | objectivize | 3 |
| 511 | non-gauze | 1 |
| 512 | 2.0mg/g | 1 |
| 513 | 218μg/g | 1 |
| 514 | 2.0ngg | 1 |
| 515 | 150ngg | 1 |
| 516 | 0.6ngg | 1 |
| 517 | 4938ngg | 1 |
| 518 | 2400μgg | 1 |
| 519 | 0.56μgg | 1 |
| 520 | 0.76μgg | 1 |
| 521 | 0.58μgg | 1 |
| 522 | -50mmhg | 1 |
| 523 | 48±12mmhg | 1 |
| 524 | 128±14mmhg | 1 |
| 525 | 79±7mmhg | 1 |
| 526 | 148mmhg | 1 |
| 527 | 1.6-kg | 1 |
| 528 | 2.58±0.24kg | 1 |
| 529 | 25gkg | 1 |
| 530 | 0.73lkg | 1 |
| 531 | hypersensitivity-inducing | 1 |
| 532 | vibration-stretching | 1 |
| 533 | non-food-advertising | 1 |
| 534 | disordered-eating | 2 |
| 535 | intuiting | 2 |
| 536 | centre-involving | 1 |
| 537 | qianshencong | 1 |
| 538 | quanzhong | 1 |
| 539 | -3.10log | 1 |
| 540 | 0.43h | 1 |
| 541 | 3.0+/-0.4h | 1 |
| 542 | 0.9±1g/24h | 1 |
| 543 | mahdiyeh | 1 |
| 544 | 102.2±26.0cmh | 1 |
| 545 | 49.2±21.1cmh | 1 |
| 546 | 4.4-month | 1 |
| 547 | bcs+wbi | 1 |
| 548 | delayed-wbi | 1 |
| 549 | gpfi | 1 |
| 550 | high-cho/high-gi | 1 |
| 551 | enyonini | 1 |
| 552 | hpsec-malls-ri | 1 |
| 553 | dementi | 1 |
| 554 | budbreak | 1 |
| 555 | 51.9/week | 1 |
| 556 | more-active/low-risk | 1 |
| 557 | 0.90mg/l | 1 |
| 558 | 110nmol/l | 1 |
| 559 | 4.5pmol/l | 1 |
| 560 | 63.2microm/l | 1 |
| 561 | 2.60+/-0.92l | 1 |
| 562 | .84l | 1 |
| 563 | .99l | 1 |
| 564 | postpharyngeal | 1 |
| 565 | nonrelational | 2 |
| 566 | late-pubertal | 1 |
| 567 | lbh589·hcl | 1 |
| 568 | 8.0gdl | 1 |
| 569 | diagnose/counsel | 1 |
| 570 | 23.4gl | 1 |
| 571 | 15gl | 1 |
| 572 | 37.6gl | 1 |
| 573 | 11.0mgl | 1 |
| 574 | 5mgl | 1 |
| 575 | 6mgl | 1 |
| 576 | 0.08mgl | 1 |
| 577 | 32microgl | 1 |
| 578 | 150μgl | 1 |
| 579 | 2.1μgl | 1 |
| 580 | 40·1nmoll | 1 |
| 581 | 84·5nmoll | 1 |
| 582 | 47·8nmoll | 1 |
| 583 | voll | 1 |
| 584 | est-ml | 4 |
| 585 | 3.07+/-0.43ng/ml | 1 |
| 586 | 207pg/ml | 2 |
| 587 | 0.8iu/ml | 1 |
| 588 | 158ml | 1 |
| 589 | 75.20ngml | 1 |
| 590 | 20.40ngml | 1 |
| 591 | l-alpha-acetylmethadol | 1 |
| 592 | 59±14mmol/mol | 1 |
| 593 | nitrosalbutamol | 1 |
| 594 | methoxyethanol | 1 |
| 595 | isopropoxyethanol | 1 |
| 596 | 2-allylphenol | 1 |
| 597 | α-retinol | 1 |
| 598 | prevent/control | 2 |
| 599 | 2,3,5-trichlorobiphenyl | 1 |
| 600 | 1-arylsulfonyl | 1 |
| 601 | 20.6mg·l | 1 |
| 602 | ≤0.62/m | 1 |
| 603 | 350mg/m | 1 |
| 604 | 133mg/m | 1 |
| 605 | 17.1±2.8j/m | 1 |
| 606 | 24.1kj/m | 1 |
| 607 | 46.2kj/m | 1 |
| 608 | 49+/-24ml/m | 1 |
| 609 | 103+/-36ml/m | 1 |
| 610 | 47+/-7ml/m | 1 |
| 611 | 48+/-7ml/m | 1 |
| 612 | 2.5l/min/m | 1 |
| 613 | 262m | 1 |
| 614 | 47.0ml/min/1.73m | 1 |
| 615 | suprasensory/sham | 1 |
| 616 | subsensory/sham | 1 |
| 617 | 80-cm | 1 |
| 618 | 300/cm | 1 |
| 619 | 673.518g/cm | 1 |
| 620 | 15-j/cm | 1 |
| 621 | 33.0cm | 1 |
| 622 | 9.0cm | 1 |
| 623 | 14cm×10cm | 1 |
| 624 | 13.4cm | 1 |
| 625 | 114.9±13.5cm | 1 |
| 626 | imepenem | 1 |
| 627 | pre-hfm | 1 |
| 628 | 314.0±36.3mohm | 1 |
| 629 | sulfamethoxazole-trimethropim | 1 |
| 630 | dihydroartemisinin-napthoquine-trimethoprim | 1 |
| 631 | 0.9kjm | 1 |
| 632 | 20000/km | 1 |
| 633 | embalm | 1 |
| 634 | nonhyperdiploid-mm | 1 |
| 635 | 160,000/mm | 1 |
| 636 | 24,500/mm | 1 |
| 637 | 23.0mm | 1 |
| 638 | 68±11mm | 1 |
| 639 | 92mm | 1 |
| 640 | 0.76mm | 1 |
| 641 | 15mj/nm | 1 |
| 642 | 3.29nm | 1 |
| 643 | 221pm | 1 |
| 644 | help/harm | 2 |
| 645 | treat/harm | 46 |
| 646 | tac-short-term | 1 |
| 647 | vtsm | 1 |
| 648 | nickel-cadmium | 1 |
| 649 | l-methyl-4-phenylpyridinium | 1 |
| 650 | 6.42n | 1 |
| 651 | 5.53n | 1 |
| 652 | 58.8n | 1 |
| 653 | polyurethan | 1 |
| 654 | 1,3-dichlorodibenzofuran | 1 |
| 655 | rmet+en | 1 |
| 656 | re-harden | 1 |
| 657 | autonomic/hypoxemia-driven | 1 |
| 658 | feign | 9 |
| 659 | gain/gain | 3 |
| 660 | phycocyanin-alpha-chain | 1 |
| 661 | retrain | 11 |
| 662 | overconstrain | 1 |
| 663 | des-cladinose-azithromycin | 1 |
| 664 | asialoglycoprotein | 1 |
| 665 | terbutalin | 1 |
| 666 | amoxicillin/ampicillin | 1 |
| 667 | 200/min | 1 |
| 668 | phytohaemaglutinin | 1 |
| 669 | placebo/warfarin | 2 |
| 670 | bacillosporin | 2 |
| 671 | teniposide+cisplatin | 1 |
| 672 | placebo/simvastatin | 1 |
| 673 | gabepentin | 1 |
| 674 | 1,3,7-trichlorodibenzo-p-dioxin | 1 |
| 675 | cefamezin | 1 |
| 676 | xaa-pro-gln | 1 |
| 677 | group-assistant-purification | 1 |
| 678 | over-stratification | 1 |
| 679 | mis-communication | 1 |
| 680 | epoxydation | 2 |
| 681 | nonsupplementation | 1 |
| 682 | d-depletion | 1 |
| 683 | hemagglutinination-inhibition | 1 |
| 684 | thrive/malnutrition | 1 |
| 685 | high-intervention | 1 |
| 686 | cortrosyn | 1 |
| 687 | nil·4h2o | 1 |
| 688 | ris2mg+placebo | 1 |
| 689 | pseudo-placebo | 4 |
| 690 | 6-azabicyclo | 1 |
| 691 | 3-benzylidene-1h-pyrrolo | 1 |
| 692 | 2h-pyrrolo | 1 |
| 693 | 1,3-dihydrothiazolo | 1 |
| 694 | 5,7:7,13-dimethanopyrazolo | 1 |
| 695 | 3,4-dihydropyrano | 1 |
| 696 | glcnacα-o-po | 1 |
| 697 | tcbt+eap | 1 |
| 698 | 2119bp | 2 |
| 699 | stenting/dep | 1 |
| 700 | spd-nepp | 1 |
| 701 | rehabilitation-group | 1 |
| 702 | permitsubgroup | 2 |
| 703 | cop-cvp | 1 |
| 704 | galα1,3-galβ1-4glcnac-r | 1 |
| 705 | 60mbar | 1 |
| 706 | 1.2°/year | 1 |
| 707 | win-together | 1 |
| 708 | factor/cluster | 1 |
| 709 | nonrollover | 1 |
| 710 | 36fr | 2 |
| 711 | dphr | 1 |
| 712 | tenofovir/emtricitabine/raltegravir | 1 |
| 713 | work.for | 1 |
| 714 | malefactor | 1 |
| 715 | 228.7ucarr | 1 |
| 716 | 144-hour | 1 |
| 717 | -1.21°/s | 1 |
| 718 | -2.96°/s | 1 |
| 719 | -1.58°/s | 1 |
| 720 | -3.29°/s | 1 |
| 721 | 0.125s | 1 |
| 722 | ltra+ics | 4 |
| 723 | 14-month-olds | 1 |
| 724 | 15-month-olds | 2 |
| 725 | 20-year-olds | 3 |
| 726 | 29-year-olds | 3 |
| 727 | 18-y-olds | 1 |
| 728 | dwi-sequences | 1 |
| 729 | macrolides-lincosamides | 1 |
| 730 | 1,3-butadienyl-1-oxoboranes | 1 |
| 731 | 1,3,5-triarylbenzenes | 2 |
| 732 | dibenzo-α-pyrones | 1 |
| 733 | gg-homozygotes | 1 |
| 734 | interweaves | 1 |
| 735 | normtensives | 1 |
| 736 | wonca-feelings | 1 |
| 737 | rapalogs | 1 |
| 738 | ufhs | 1 |
| 739 | 50months | 1 |
| 740 | 2.3months | 1 |
| 741 | post-prophylaxis | 1 |
| 742 | 397±23ms | 1 |
| 743 | 409±27ms | 1 |
| 744 | growth-transforms | 1 |
| 745 | oxacillins | 1 |
| 746 | non-evslns | 1 |
| 747 | pads/tampons | 1 |
| 748 | later-borns | 2 |
| 749 | non-afternoon-snackers | 1 |
| 750 | non-harvesters | 1 |
| 751 | α3β4-nachrs | 1 |
| 752 | undress | 1 |
| 753 | mid-parts | 1 |
| 754 | midannulus | 1 |
| 755 | letrozole/everolimus | 1 |
| 756 | 4.8days | 1 |
| 757 | self-heat | 2 |
| 758 | treat | 13,745 |
| 759 | self-treat | 15 |
| 760 | prevent/treat | 9 |
| 761 | overtreat | 5 |
| 762 | cross-infect | 1 |
| 763 | self-inject | 2 |
| 764 | comparison-target | 1 |
| 765 | untarget | 1 |
| 766 | ima/height | 2 |
| 767 | autosomal-co-dominant | 1 |
| 768 | immunosilent | 1 |
| 769 | direct-measurement | 1 |
| 770 | correct/augment | 1 |
| 771 | photodocument | 1 |
| 772 | first-and-subsequent | 3 |
| 773 | 1-sqrt | 1 |
| 774 | nhs-post | 1 |
| 775 | pf-tafluprost | 1 |
| 776 | cbtp+tau | 1 |
| 777 | zhongzangfu | 1 |
| 778 | wrodclaw | 1 |
| 779 | twice-in-a-row | 1 |
| 780 | 9msw | 1 |
| 781 | α-y | 1 |
| 782 | 540-day | 1 |
| 783 | different-day | 1 |
| 784 | 151/day | 1 |
| 785 | 5.5/day | 1 |
| 786 | 138/day | 1 |
| 787 | 1gy | 1 |
| 788 | £9951/qaly | 1 |
| 789 | thermometrically | 2 |
| 790 | supramodally | 1 |
| 791 | quit-only | 1 |
| 792 | ''early | 1 |
| 793 | endartectomy | 1 |
| 794 | colophony | 7 |
| 795 | chemo-somatosensory | 1 |
| 796 | keyality | 1 |
| 797 | non-ignorability | 1 |
| 798 | infinity | 207 |
| 799 | 20alpha-hydroxy | 1 |
| 800 | tenofovir-df/emtricitabine/efavirenz | 1 |
| 801 | prolastinæ | 1 |
| 802 | myobloc® | 1 |
| 803 | prostascint® | 1 |
| 804 | 258° | 1 |
| 805 | 〈λ〉ζ | 1 |